Document:

EX-4.2

 Exhibit 4.2 

Execution Version 

KODIAK SCIENCES INC. 

INVESTORS’ RIGHTS AGREEMENT 

THIS INVESTORS’ RIGHTS AGREEMENT (this
“Agreement”) is made and entered into as of September 8, 2015, by and among KODIAK SCIENCES INC., a Delaware
corporation (the “Company”), and each of the stockholders of the Company that has delivered a signature page hereto (the “Investors”). 

RECITALS 

WHEREAS, concurrently with the execution of this Agreement, the Company and certain of the
Investors (the “Purchasers”) are entering into a Series B Preferred Stock Purchase Agreement (the “Purchase Agreement”) pursuant to which the Company will issue and sell to the Purchasers shares of the
Company’s Series B Preferred Stock, and the Purchasers will purchase such shares of Series B Preferred Stock on the terms and subject to the conditions set forth in the Purchase Agreement; 

WHEREAS, the Company’s and the Purchasers’ respective obligations under the Purchase
Agreement are conditioned upon the execution of this Agreement as set forth herein; and 
 WHEREAS,
in connection with the conversion of the Company from a limited liability company to a corporation, the Company desires to give the holders of the Company’s Series A Preferred Stock certain rights hereunder. 

NOW, THEREFORE, in consideration of the foregoing recitals and the mutual covenants
and agreements herein contained, the parties hereto agree as follows: 
  

	1.	Definitions. 

 “1933 Act” means the Securities Act of 1933, as
amended. 
 “1934 Act” means the Securities Exchange Act of 1934, as amended. 

“Affiliate” means, with respect to any Person, any other Person that, directly or indirectly, controls, is controlled
by, or is under common control with such Person. 
 “Certificate” means the Company’s Certificate of
Incorporation, as amended from time to time. 
 “Common Stock” means the Company’s common stock, par value
$0.0001 per share. 
 “Conversion Securities” means (i) any Common Stock held by an Investor, (ii) any
Common Stock issuable or issued upon conversion of the Preferred Stock now held or hereafter acquired by an Investor or as a dividend or other distribution with respect to, in exchange for, or in replacement of the Preferred Stock now held or
hereafter acquired by an Investor, (iii) any Common Stock issuable or issued upon exercise of any warrants to purchase Common Stock (or exercise and conversion of warrants to purchase Preferred Stock) held by an Investor or as a distribution
with respect to, in exchange for, or in 

 replacement of any warrants to purchase Common Stock (or Preferred Stock) held by an Investor,
and (iv) any Common Stock issued as a dividend or other distribution with respect to, in exchange for, or in replacement of any of the Common Stock that constitutes Conversion Securities pursuant to (i), (ii) and (iii) above. 

“Form S-1,” “ Form
S-3,” “Form S-4” and “Form S-8” mean such respective forms under the
1933 Act, as in effect on the date hereof or any successor registration forms to Form S-1, Form S-3, Form S-4 and Form S-8, respectively, under the 1933 Act subsequently adopted by the U.S. Securities and Exchange Commission (the “SEC”) that, with respect to Form S-3,
Form S-4 and Form S-8, permit (with the exception of Form S-4, in the case of any offering registered thereon) incorporation of
substantial information by reference to other documents filed by the Company with the SEC. 
 “GAAP” means generally
accepted accounting principles in the United States of America. 
 “Holder” means any Investor owning Registrable
Securities (as defined below) or any assignee thereof in accordance with Section 2(m) hereof. 

“Immediate Family” means, with respect to any natural person, each of such person’s spouse, father, mother,
brothers, sisters, aunts, uncles, nieces and nephews and lineal descendants and ancestors. 
 “IPO” means the
Company’s first sale of Common Stock in a public offering pursuant to a registration statement under the 1933 Act and in connection with which shares of Common Stock are admitted to trading on an internationally recognized stock market or
quotation system. 
 “New Securities” means equity securities of the Company, whether now or hereafter authorized, or
rights, options or warrants to purchase said equity securities, or securities of any type whatsoever that are, or may become, convertible into or exchangeable (directly or indirectly) into or exercisable for said equity securities. 

“Person” means any individual or entity. 

“Preferred Stock” means the Company’s preferred stock authorized, issued and outstanding from time to time. 

“Qualified IPO” means the Company’s first sale of Common Stock in a firm commitment underwritten public offering
pursuant to a registration statement under the 1933 Act at a per share public offering price (prior to underwriter commissions and expenses) of at least $10.00 (as adjusted for stock splits, combinations, dividends and the like) and that results in
aggregate gross cash proceeds to the Company of an amount equal to or greater than $75,000,000 (before deduction of underwriting discounts, commissions and expenses). 

  
 -2- 

 “Register,” “registered” and
“registration” refer to a registration effected by preparing and filing a registration statement or similar document in compliance with the 1933 Act, and the automatic effectiveness or the declaration or ordering of
effectiveness of such registration statement or document. 
 “Registrable Securities” means any Conversion
Securities; excluding in all cases, (i) any shares previously sold pursuant to a registered public offering or pursuant to an exemption from the registration requirements of the 1933 Act under which the transferee does not receive
“restricted securities,” (ii) any shares otherwise sold by a person in a transaction in which his, her or its rights under Section 2 are not assigned pursuant to Section 2(m), and
(iii) any shares for which the registration rights have terminated pursuant to Section 2(o). 
 A
“Subsidiary” of any Person means another Person, an amount of the voting securities, other voting ownership or voting partnership interests of which is sufficient to elect at least 50% of its board of directors or other
governing body (or, if there are no such voting interests, 50% or more of the equity interests of which) is owned directly or indirectly by such first Person. 
  

	2.	Registration Rights. 

 (a) Request for Registration. 

(1) If the Company shall receive at any time following the earlier of December 31, 2020 or 180 days after the effective date of the IPO, a
written request from one or more Holders holding at least 50% of the Registrable Securities (on an as-converted into Common Stock basis) (the Holders initiating such request, the “Initiating
Holders”) that the Company effect the registration under the 1933 Act of Registrable Securities with an anticipated aggregate offering price of at least $30,000,000, then the Company shall: 

(i) within ten (10) days of the receipt thereof, give written notice of 

such request to all Holders, 
 (ii) subject to
the limitations of this Section 2(a), use its commercially reasonable efforts to effect a registration under the 1933 Act of all of such Initiating Holders’ Registrable Securities as are specified in such request,
together with all of the Registrable Securities of any other Holder or Holders joining in such request as are specified in a written request given within twenty (20) days after receipt of such written notice from the Company as soon as
practicable, and 
 (iii) file, as promptly as reasonably practicable following receipt of such request of the Initiating Holders in all
other cases, a registration statement under the 1933 Act covering all the Registrable Securities that the Holders shall in writing request to be included in such registration and to use its commercially reasonable efforts to have such registration
statement declared effective. 

  
 -3- 

 (2) If the Initiating Holders intend to distribute the Registrable Securities covered by their
request by means of an underwriting, they shall so advise the Company as part of their request made pursuant to this Section 2(a) and the Company shall include such information in the written notice referred to in
Section 2(a)(i). In such event, the right of any Holder to include its Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such
Holder’s Registrable Securities in the underwriting (unless otherwise mutually agreed upon by the Company, Initiating Holders holding or having the right to receive at least a majority of the Registrable Securities that all Initiating Holders
own or have the right to receive, and such Holder) to the extent provided herein. All parties proposing to distribute their securities through such underwriting shall (together with the Company as provided in
Section 2(d)(5)) enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting by the Board of Directors of the Company (the “Board”) and
reasonably acceptable to a majority in interest of the Holders. Notwithstanding any other provision of this Section 2(a), if, in the case of a registration requested pursuant to Section 2(a), the
underwriter advises the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise the Company and all Holders of Registrable Securities which
would otherwise be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated pro rata among all Holders thereof desiring to participate in such underwriting (proportionate to
the number of Registrable Securities then held by each such Holder). No Registrable Securities requested by any Holder to be included in a registration pursuant to Section 2(a) shall be excluded from the underwriting unless
all securities other than Registrable Securities are first excluded (including any securities to be offered by the Company). To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriter may round the
number of shares allocated to any Holder to the nearest 100 shares. 
 (3) Notwithstanding the foregoing provisions of this
Section 2(a), the Company shall not be obligated to effect, or take action to effect any registration pursuant to Section 2(a) after the Company has already effected two registrations initiated by
the Holders pursuant to Section 2(a); provided, however, that no registration of Registrable Securities that shall not have become and remained effective in accordance with
Section 2(d) shall be deemed to be a registration for any purpose of this Section 2(a) unless such registration was withdrawn at the request of the Holders except under the circumstances described in the last clause of
the first sentence of Section 2(f). 
 (4) Notwithstanding the foregoing provisions of this
Section 2(a), in the event that the Company is requested to file any registration statement pursuant to this Section 2(a), the Company shall not be obligated to effect the filing of such
registration statement: 
 (i) during the 90-day period following the effective date of any other
registration statement on Form S-1 or S-3 pertaining to an underwritten public offering of securities for the account of the Company or any Holder; or 

  
 -4- 

 (ii) in any particular jurisdiction in which the Company would be required to execute a general
consent to service of process in effecting such registration, unless the Company is already subject to service in such jurisdiction and except as may be required under the 1933 Act; or 

(iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Section 2(c) below; or 
 (iv) if the
Registrable Securities to be included in the registration statement could be sold without restriction of any manner under Rule 144 of the 1933 Act within a 90-day period and the Company is currently subject to
the periodic reporting requirements of Sections 12(g) or 15(d) of the 1934 Act; or 
 (v) if the Company shall furnish to the Holders
requesting such registration statement a certificate signed by the Chief Executive Officer of the Company stating that, in the good faith judgment of the Board (as evidenced by a written resolution of the Board), it would not be in the best
interests of the Company and its stockholders generally for such registration statement to be filed or to remain effective as long as such registration statement would otherwise be required to remain effective, the Company shall have the right to
defer such filing for a period of not more than 180 days after receipt of the request for registration from the applicable Initiating Holders; provided, however, that the Company may not utilize the right set forth in this
Section 2(a)(4)(v) more than once in any twelve-month period. 
 (b) Company Registration. If after the
closing of the IPO the Company proposes (but without any obligation to do so) to register (including for this purpose a registration effected by the Company for stockholders other than the Holders) any of its capital stock or other equity securities
(or securities convertible into equity securities) under the 1933 Act in connection with the public offering of such securities (other than a registration on Form S-8 relating solely to the sale of securities
to participants in a Company stock plan, a registration relating to a transaction described in Rule 145(a) of the 1933 Act, or a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities
that are also being registered or a registration on Form S-4), the Company shall, at such time, promptly give each Holder of any Registrable Securities written notice of such registration. Upon the written
request of any such Holder, given within ten (10) days after mailing of such notice by the Company, the Company shall, subject to the provisions of Section 2(h) and the following sentence of this
Section 2(b), use its commercially reasonable efforts to cause a registration statement covering all of the Registrable Securities that each such Holder has requested to be registered to become effective under the 1933 Act.
The Company shall have the right, in its sole discretion, to terminate or withdraw, and shall otherwise be under no obligation to complete, any offering of its securities it proposes to make under this Section 2(b) and
shall incur no liability to any Holder for its failure to do so, whether or not such Holder has elected to include securities in such registration. The expenses of such withdrawn registration shall be paid by the Company in accordance with
Section 2(f). 

  
 -5- 

 (c) Form S-3 Registration. 

(1) In case the Company shall receive from one or more Holders a written request or requests that the Company effect a registration on Form S-3 (or on any successor form to Form S-3 regardless of its designation) and any related qualification or compliance with respect to all or a part of the Registrable
Securities owned by such Holder or Holders, the Company will: 
 (i) promptly give written notice of the proposed registration, and any
related qualification or compliance, to all other Holders; and 
 (ii) use its commercially reasonable efforts to effect such registration
as soon as practicable, and in any event, to file within ninety (90) days of the receipt of such request a registration statement under the 1933 Act on Form S-3 covering all of the Registrable Securities
which such Holders have requested to be registered and to use its commercially reasonable efforts to have such registration statement become effective, and to effect such qualification or compliance as may be so requested and as would permit or
facilitate the sale and distribution of all or such portion of such Holder’s or Holders’ Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of any other Holder or
Holders joining in such request as are specified in a written request given within twenty (20) days after receipt of such written notice from the Company; provided, however, that the Company shall not be obligated to effect any
such registration, qualification or compliance pursuant to this Section 2(c) if: (1) Form S-3 (or any successor form to Form S-3
regardless of its designation) is not available for such offering by the Holders; (2) the aggregate gross proceeds (before deduction of underwriting discounts and commissions) of the Registrable Securities specified in such request is less than
$10,000,000; (3) the Company shall furnish to the Holder or Holders requesting a registration statement pursuant to this Section 2(c) a certificate signed by the Company’s Chief Executive Officer stating that, in the
good faith judgment of the Board (as evidenced by a written resolution of the Board), it would not be in the best interests of the Company and its stockholders generally for such registration statement to be filed, in which event the Company shall
have the right to defer such filing for a period of not more than one hundred eighty (180) days after receipt of the request of such Holder or Holders, provided that such right shall be exercised by the Company not more than once in any twelve
(12)-month period; (4) the Company shall have effected three registrations pursuant to this Section 2(c); or (5) with respect to any particular jurisdiction, the Company would be required to qualify to do business or
to execute a general consent to service of process in effecting such registration, qualification or compliance, unless the Company is already subject to service in such jurisdiction and except as may be required under the 1933 Act; or
(6) during the period ending one hundred eighty (180) days after the effective date of a registration statement filed pursuant to Section 2(a). 

(2) If the Holders intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise
the Company as part of their request made pursuant to this Section 2(c) and the Company shall include such information in the written notice referred to in Section 2(c)(1)(i). The provisions of
Section 2(a)(2) shall be applicable to such request (with the substitution of Section 2(c) for references to Section 2(a)). 

  
 -6- 

 (d) Obligations of the Company. Whenever required under this
Section 2 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably practicable: 

(1) prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable
efforts to cause such registration statement to become effective, and, upon the request of the Holders of at least a majority of the Registrable Securities registered thereunder, keep such registration statement effective for up to 90 days or until
such earlier time at which the distribution of securities contemplated by such registration statement has been completed (such 90-day or shorter period, the “Effectiveness
Period”); 
 (2) prepare and file with the SEC such amendments and supplements to such registration statement and the
prospectus used in connection with such registration statement, and use its commercially reasonable efforts to cause each such amendment and supplement to become effective, as may be necessary to comply with the provisions of the 1933 Act with
respect to the disposition of all securities covered by such registration statement during the Effectiveness Period; 
 (3) furnish to the
Holders, such number of copies of a prospectus, including a preliminary prospectus, in conformity with the requirements of the 1933 Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable
Securities owned by them; 
 (4) use its commercially reasonable efforts to register or qualify the securities covered by such registration
statement under such other securities or Blue Sky laws of such states and jurisdictions as shall be reasonably requested by the Holders, except that the Company shall not be required in connection therewith or as a condition thereto to
qualify to do business, subject itself to taxation or file a general consent to service of process in any such state or jurisdiction; 
 (5)
in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriter of such offering. Each Holder participating in such underwriting
shall also enter into and perform its obligations under such an underwriting agreement, including furnishing an opinion of counsel or entering into a lock-up agreement required pursuant to the provisions of
Section 2(l); 
 (6) notify each Holder covered by such registration statement, at any time when a prospectus
relating thereto covered by such registration statement is required to be delivered under the 1933 Act, of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue
statement of a material fact or omits to state a material fact required to be stated therein or necessary to make 

  
 -7- 

 
the statements therein, in the light of the circumstances under which they were made, not misleading, and promptly file such amendments and supplements which may be required pursuant to
Section 2(d)(2) on account of such event and use its commercially reasonable efforts to cause each such amendment and supplement to become effective; 

(7) use its commercially reasonable efforts to have furnished, at the request of any Holder requesting registration of Registrable Securities
pursuant to this Section 2, if such securities are being sold through underwriters, to such underwriters on the date that such Registrable Securities are delivered to the underwriters for sale in connection with a
registration pursuant to this Section 2: (i) an opinion or opinions, dated such date, of the counsel representing the Company for the purposes of such registration, in form and substance as is customarily given by company
counsel to the underwriters in an underwritten public offering, addressed to the underwriters, if any, and (ii) a “comfort” letter dated such date, from the independent certified public accountant of the Company, in form and substance
as is customarily given by independent certified public accountants to underwriters in an underwritten public offering, addressed to the underwriters, if any; 

(8) apply for listing and use its commercially reasonable efforts to list the Registrable Securities being registered on any national
securities exchange on which a class of the Company’s equity securities is then listed (or in the case of a registration pursuant to Section 2(a), such national securities exchange as is requested by the Initiating Holders
and agreed to by the Company); 
 (9) notify each selling Holder, promptly after the Company receives notice thereof, of the time when such
registration statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; 

(10) after such registration statement becomes effective, notify each selling Holder in writing of any request by the SEC that the Company
amend or supplement such registration statement or prospectus; 
 (11) provide a transfer agent and registrar for all Registrable Securities
registered pursuant hereto and a CUSIP number for all such Registrable Securities, in each case not later than on the effective date of such registration; 

(12) notwithstanding any other provisions of this Agreement, from and after the time a registration statement filed under this
Section 2 covering Registrable Securities is declared effective, the Company shall have the right to suspend the registration statement and the related prospectus in order to prevent premature disclosure of any material non-public information related to corporate developments by delivering notice of such suspension to the Holders, provided, however, that the Company may exercise the right to such suspension only once
in any consecutive twelve (12) month period and for a period not to exceed ninety (90) days. From and after the date of a notice of suspension under this Section 2(d)(12), each Holder agrees not to use the registration statement or
the related prospectus for resale of any Registrable Security until the earlier of (1) notice from the Company that such suspension has been lifted or (2) the ninetieth (90) day following the giving of the notice of suspension; and 

  
 -8- 

 (13) without in any way limiting the types of registrations to which this
Section 2 shall apply, in the event that the Company shall effect a “shelf registration” on Form S-1 or Form S-3 under Rule 415
promulgated under the 1933 Act, the Company shall take all reasonable action, including, without limitation, the filing of post-effective amendments, to permit the Holders to include their Registrable Securities in such registration in accordance
with the terms of this Section 2. 
 (e) Furnish Information. It shall be a condition precedent to the
obligations of the Company to take any action pursuant to this Section 2 in respect of the Registrable Securities of any selling Holder that such selling Holder shall furnish to the Company such information regarding
itself, the Registrable Securities and the intended method of disposition of such securities, as shall be reasonably requested by the Company in connection with registration of its Registrable Securities. 

(f) Expenses of Demand Registration. All expenses other than underwriters’ or brokers’ discounts and commissions relating to
Registrable Securities incurred in connection with each registration, filing or qualification pursuant to Section 2(a), including (without limitation) all registration, filing and qualification fees, printing and accounting
fees, fees and disbursements of counsel for the Company, and the reasonable fees and disbursements of one counsel for the selling Holders (up to a maximum amount of $50,000), shall be borne and paid by the Company; provided, however,
that the Company shall not be required to pay for any expenses of any registration begun pursuant to Section 2(a) if the registration request is subsequently withdrawn at any time at the request of the Holders of a majority
of the Registrable Securities to be registered in such registration (in which case all participating Holders shall bear such expenses pro rata in accordance with the number of Registrable Securities that were to be registered thereunder by each such
Holder), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one demand registration pursuant to Section 2(a). All underwriters’ and brokers’ discounts and commissions
relating to Registrable Securities included in any registration effected pursuant to Section 2(a) will be borne and paid ratably by the Holders of such Registrable Securities. 

(g) Expenses of Company Registration and Form S-3 Registration. The Company shall bear and pay
all expenses incurred in connection with any registration, filing or qualification of Registrable Securities with respect to any registration pursuant to Section 2(b) or Section 2(c) for each
Holder including, without limitation, all registration, filing and qualification fees, printing and accounting fees, fees and disbursements of counsel for the Company and the reasonable fees and disbursements of one counsel for the selling Holders
(up to a maximum amount of $20,000). Underwriters’ and brokers’ discounts and commissions relating to Registrable Securities included in any registration effected pursuant to Section 2(b) or
Section 2(c) will be borne and paid ratably by the Holders of such Registrable Securities on the basis of the number of Registrable Securities registered on their behalf. 

  
 -9- 

 (h) Underwriting Requirements in Company Registration. In connection with any offering
involving an underwriting of securities being issued by the Company, the Company shall not be required under Section 2(b) to include any of the Holders’ securities in such underwriting unless such Holders accept the
terms of the underwriting as agreed upon between the Company and the underwriters selected by it, and then only in such quantity, if any, as the underwriters determine in their sole discretion, marketing factors allow. If the managing underwriter
for the offering shall advise the Company in writing that the total amount of securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the amount of securities to be sold other than by the
Company that marketing factors allow, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the managing underwriter believes marketing factors allow (the
securities so included to be reduced as follows: (a) all securities which stockholders other than the Company and the Holders seek to include in the offering shall first be excluded from the offering to the extent limitation on the number of
shares included in the underwriting is required, and (b) if further limitation on the number of shares to be included in the underwriting is required, then the number of shares held by the Holders that may be included in the underwriting shall
be reduced pro rata in accordance with the number of Registrable Securities held by each such Holder at the time of such offering, but in no event shall the amount of securities of the selling Holders included in the offering be reduced below 25% of
the total amount of securities included in such offering, other than the Company’s IPO in which case the number of shares held by the Holders that may be included in the underwriting may be cut back to zero). For purposes of the preceding
parenthetical concerning apportionment, for any selling stockholder that is a Holder of Registrable Securities and that is a venture capital fund, a partnership, a limited liability company or a corporation, the affiliated venture capital funds,
partners, retired partners, members, retired members and stockholders of such Holder, or the estates and family members of such partners, retired partners, members and retired members and any trusts for the benefit of any of the foregoing persons
shall collectively be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate amount of shares carrying registration rights owned by all entities
and individuals included in such “selling Holder,” as defined in this sentence. 
 (i) Delay of Registration. No Holder
shall have any right to obtain or seek an injunction restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this
Section 2. 
 (j) Indemnification. In the event any Registrable Securities are included in a registration
statement under this Section 2: 
 (1) To the extent permitted by law, the Company will indemnify and hold harmless
each Holder, the officers, directors, partners, members, agents and employees of each Holder, legal counsel and accountants for each such holder, any underwriter (as defined in the 1933 Act) for such Holder and each person, if any, who controls such
Holder or underwriter or other aforementioned person within the meaning of the 1933 Act or the 1934 Act, against any losses, claims, damages or liabilities (joint or several) to which they may become subject under the 1933 Act, the 1934 Act or any
other federal or state law, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations (each a “Violation”):
(i) any untrue statement or 

  
 -10- 

 
alleged untrue statement of a material fact contained in such registration statement, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements
thereto, any issuer information (as defined in Rule 433 of the 1933 Act) filed or required to be filed pursuant to Rule 433(d) under the 1933 Act, (ii) the omission or alleged omission to state therein a material fact required to be stated
therein or necessary to make the statements therein, in light of the circumstances in which they were made in the case of any prospectus, not misleading, or (iii) any violation or alleged violation by the Company of the 1933 Act, the 1934 Act,
any state or federal securities law or any rule or regulation promulgated under the 1933 Act, the 1934 Act or any state or federal securities law in connection with any matter relating to such registration statement. The Company will promptly
reimburse each such Holder, officer, director, partner, member, agent, employee, legal counsel, accountants, underwriter or controlling person for any legal or other expenses reasonably incurred by them in connection with investigating or defending
any such loss, claim, damage, liability, or action, as incurred. The indemnity agreement contained in this Section 2(j)(1) shall not apply to amounts paid in settlement of any loss, claim, damage, liability or action if
such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld, conditioned or delayed), nor shall the Company be liable to a Holder in any such case for any such loss, claim, damage, liability or
action to the extent that it arises out of or is based upon (i) a Violation that occurs in reliance upon and in conformity with written information furnished to the Company expressly for use in such registration by or on behalf of such Holder
or (ii) in the case of a sale directly by a Holder of Registrable Securities (including a sale of such Registrable Securities through any underwriter retained by such Holder engaging in a distribution solely on behalf of such Holder), an untrue
statement or alleged untrue statement or omission or alleged omission that was contained in a preliminary prospectus and corrected in a final, amended or supplemented prospectus (including a free writing prospectus) delivered to such Holder or
underwriter a reasonable period of time prior to the time of such sale, and such Holder or underwriter failed to deliver a copy of such final, amended or supplemented prospectus (including a free writing prospectus) at or prior to the time of sale
of the Registrable Securities to the person asserting any such loss, claim, damage or liability in any case in which the delivery of such final, amended or supplemented prospectus (including a free writing prospectus) would have eliminated such
loss, claim, damage or liability. 
 (2) Each Holder that includes any Registrable Securities in any registration statement will furnish to
the Company in writing such information as the Company reasonably requests for use in connection with any registration statement or prospectus and agrees to indemnify and hold harmless the Company, each of its directors, each of its officers who
have signed the registration statement, each person, if any, who controls the Company within the meaning of the 1933 Act, each other selling Holder and each person, if any, who controls a selling Holder within the meaning of the 1933 Act against any
losses, claims, damages, or liabilities (joint or several) to which the Company or any such director, officer, Holder or controlling person may become subject, under the 1933 Act, the 1934 Act or any other federal or state law, insofar as such
losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such Violation occurs in reliance upon and in conformity with written
information furnished to the Company by or on behalf of such Holder expressly for use in such registration, and each such 

  
 -11- 

 
Holder will promptly reimburse any legal or other expenses reasonably and actually incurred by the Company or any such director, officer, Holder or controlling person in connection with
investigating or defending any such loss, claim, damage, liability, or action, as incurred; provided, however, that the liability of any Holder hereunder shall be limited to the proceeds from the offering received by such Holder (net
of any underwriting discounts, commissions or other selling expenses); and provided, further, that the indemnity agreement contained in this Section 2(j)(2) shall not apply to amounts paid in settlement of any
such loss, claim, damage, liability or action if such settlement is effected without the consent of the Holder (which consent shall not be unreasonably withheld, conditioned or delayed), nor, in the case of a sale directly by the Company of its
securities (including a sale of such securities through any underwriter retained by the Company to engage in a distribution solely on behalf of the Company), shall the Holder be liable to the Company in any case in which such untrue statement or
alleged untrue statement or omission or alleged omission was contained in a preliminary prospectus and corrected in a final, amended or supplemented prospectus (including a free writing prospectus), and the Company or such underwriter failed to
deliver a copy of such final, amended or supplemented prospectus (including a free writing prospectus) at or prior to the time of sale of the securities to the person asserting any such loss, claim, damage or liability and the delivery of such
final, amended or supplemented prospectus (including a free writing prospectus) would have eliminated such loss, claim, damage or liability. The obligations of the Holders hereunder are several, not joint. 

(3) Promptly after receipt by an indemnified party under this Section 2(j) of notice of the commencement of any
action (including any governmental action) for which the party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this
Section 2(j), deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly
with any other indemnifying party similarly noticed, to assume and control the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties
that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the
indemnifying party would be inappropriate due to actual or potential differing interests, as reasonably determined by either party, between such indemnified party and any other party represented by such counsel in such proceeding. The failure to
deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action, if materially prejudicial to its ability to defend such action, shall relieve such indemnifying party of liability to the indemnified
party under this Section 2(j) to the extent, and only to the extent, of such prejudice. 
 (4) In order to provide
for just and equitable contribution to joint liability under the 1933 Act in any case in which either (i) any indemnified party exercising rights under this Agreement, or any controlling person of any such indemnified party, makes a claim for
indemnification pursuant to this Section 2(j) but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or 

  
 -12- 

 
the denial of the last right of appeal) that such indemnification may not be enforced in such case notwithstanding the fact that this Section 2(j) provides for
indemnification in such case, or (ii) contribution under the 1933 Act may be required on the part of any such indemnifying party or any such controlling person in circumstances for which indemnification is provided under this
Section 2(j), then, and in each such case, the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such loss,
liability, claim, damages or expense in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and the indemnified party on the other hand in connection with the statements or omissions that
resulted in such loss, liability, claim, damages or expense, as well as any other relevant equitable considerations; provided, however, that no contribution by any Holder, when combined with any other amounts paid by such Holder
pursuant to this Section 2(j), shall exceed the aggregate net proceeds received by such Holder in the offering. The relative fault of the indemnifying party and the indemnified party shall be determined by reference to,
among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the
parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the 1933 Act) shall be
entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. Notwithstanding the foregoing, in no event shall such Holder’s liability pursuant to this Section 2(j)(4), when combined
with any amounts paid or payable by such Holder pursuant to Section 2(j)(2), exceed proceeds from the offering received by such Holder (net of any underwriting discounts, commissions or other selling expenses). 

(5) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten offering, the obligations of the
Company and the Holders under this Section 2(j) shall survive the sale, if any, of the Registrable Securities and the completion of any offering of Registrable Securities in a registration statement. 

(k) Reports Under the 1934 Act. With a view to making available to the Holders the benefits of Rule 144 promulgated under the 1933 Act
(“Rule 144”) and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration, and with a view to making it possible for Holders to have the
resale of the Registrable Securities registered pursuant to a registration statement on Form S-3, the Company shall use its commercially reasonable efforts to: 

(i) make and keep adequate public information available, as those terms are understood and defined in Rule 144, at all times after the
effective date of the registration statement for the IPO and for so long as the Company is subject to the periodic reporting requirements under Section 13 or Section 15(d) of the 1934 Act; 

(ii) following the closing of the IPO, take such action, including the voluntary registration of its Common Stock under Section 12 of the
1934 Act or compliance with the reporting requirements of Section 15(D) of the 1934 Act, as is necessary to enable the Holders to utilize Form S-3 for the sale of their Registrable Securities; 

  
 -13- 

 (iii) after the closing of the IPO, file with the SEC in a timely manner all reports and other
documents required of the Company under the 1933 Act and the 1934 Act; and 
 (iv) furnish to any Holder, so long as the Holder owns any
Registrable Securities, forthwith upon request (1) a written statement by the Company as to its compliance with the reporting requirements of Rule 144 (at any time after 90 days after the closing of the IPO), the 1933 Act and the 1934 Act (at
any time after it has become subject to such reporting requirements), or as to its qualification as a registrant whose securities may be resold pursuant to Form S-3 (at any time after it so qualifies), (2) a
copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company, and 
 (3) such other
documents as may be reasonably requested in availing any Holder of any rule or regulation of the SEC which permits the selling of any such securities without registration or pursuant to such form. 

(l) Lock-up Agreement. 

(1) If requested by the Company and/or any underwriters managing the IPO, each Investor agrees to not, and to enter into a lock-up agreement in the form proposed by the Company and/or the underwriters pursuant to which such Investor will not, (i) lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase,
purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities of the Company convertible into or exercisable or
exchangeable for Common Stock owned by the Investor as of the effective date of the IPO, except the Registrable Securities sold in the IPO, or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of
the economic consequences of ownership of such Common Stock, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash or otherwise, without the prior consent of
the Company or the underwriter, provided that such lock-up time period shall not exceed 180 days from the effective date of the IPO or, if required by such underwriter, such longer period of time as is
necessary to enable such underwriter to issue a research report or make a public appearance that relates to an earnings release or announcement by the Company within 18 days before or after the date that is 180 days after the effective date of the
registration statement relating to such IPO, but in any event not to exceed 198 days following the effective date of the registration statement relating to such IPO; provided further that nothing in this
Section 2(l) shall prohibit, and any lock-up agreement entered into hereunder shall permit, the transfer by a Holder to a member of such Holder’s Immediate Family or to an
Affiliate of such Holder, so long as such transferee also agrees to enter into and be bound by a lock-up agreement substantially identical to the lock-up agreement
required by this Section 2(l). Any such lock up shall not apply to any Common Stock or any other securities purchased by an Investor in the IPO or any time subsequent to the IPO. In order to enforce the foregoing covenant,
the Company may impose stop-transfer instructions with respect to the 

  
 -14- 

 
securities of each Investor (and the shares of securities of every other person subject to the foregoing restriction) until the end of such period. Any underwriter, in connection with an
underwritten offering pursuant to this Agreement, is an intended third-party beneficiary of this Section 2(l) and shall have the right, power and authority to enforce the provision hereof as though it were a party hereto.

 (2) Each Investor agrees that a legend reading substantially as follows shall be placed on all certificates representing the securities of
each Investor to be subject to such lock up (and the shares or securities of every other person subject to the restriction contained in this Section 2(l) until the expiration of the
lock-up period): 
 “THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A LOCK-UP PERIOD AFTER THE EFFECTIVE DATE OF CERTAIN OF THE ISSUER’S REGISTRATION STATEMENTS FILED UNDER THE SECURITIES ACT, AS MAY BE AMENDED FROM TIME TO TIME, AS SET FORTH IN AN AGREEMENT BETWEEN THE COMPANY
AND THE ORIGINAL HOLDER OF THESE SECURITIES, AS MAY BE AMENDED FROM TIME TO TIME, A COPY OF WHICH IS ON FILE IN THE OFFICE OF THE SECRETARY OF THE ISSUER. SUCH LOCK-UP PERIOD IS BINDING ON TRANSFEREES OF THESE
SHARES.” 
 (m) Assignment of Registration Rights. The rights to cause the Company to register Registrable Securities pursuant to
this Section 2 may be assigned by any Holder to a “permitted transferee” pursuant to this Section 2(m) and by such transferee to a subsequent permitted transferee, but only if such rights
are transferred with all related obligations hereunder. A “permitted transferee” means (a) (i) an Affiliate of such Holder or transferee, (ii) any member or members of such Holder’s Immediate Family or a trust for the
benefit of any member or members of such Holder’s Immediate Family, if by gift or bequest or through inheritance to, or for the benefit of, such person, (iii) a trust in respect of which such Holder serves as trustee, provided,
however, that the trust instrument governing such trust shall provide that such Holder, as trustee, shall retain sole and exclusive control over the voting and disposition of such rights until the termination of this Agreement, or (iv) a
limited partnership or limited liability company, all partners or members of which are members of such Holder’s Immediate Family, or (b) any person in connection with the sale or other transfer of at least an aggregate of 300,000 shares of
such Holder’s Registrable Securities (as adjusted for stock splits, combinations, stock dividends and recapitalizations). No transfer may be made pursuant to this Section 2(m) to a transferee reasonably determined in
good faith by written resolution of the Board to be, directly or indirectly, a competitor of the Company. In addition, no transfer may be made pursuant to this Section 2(m), unless (A) the intended permitted transferee
to whom rights under this Agreement are transferred shall have, as a condition to such transfer, previously delivered to the Company a written instrument by which such permitted transferee agrees to be bound by the obligations imposed upon Holders
under this Agreement to the same extent as if such transferee were a 

  
 -15- 

 
Holder under this Agreement, (B) within a reasonable amount of time prior to such transfer the Company shall have been furnished with written notice of such transferee’s name and
address, and the securities with respect to which such registration rights are being assigned; and (C) following such transfer, the further disposition of such Registrable Securities by the permitted transferee is restricted under the 1933 Act. 

(n) Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the prior
written consent of the Holders of a majority of the Registrable Securities (assuming for these purposes the conversion of the Registrable Securities into Common Stock), enter into any agreement with any holder or prospective holder of any securities
of the Company relating to registration rights unless such agreement includes: 
 (a) to the extent such agreement would allow such holder or prospective
holder to include such securities in any registration statement filed under Section 2(a), 2(b) or 2(c) hereof, a provision that such holder or prospective holder may include such securities in any such
registration only to the extent that the inclusion of its securities will not reduce the amount of the Registrable Securities of the Holders that would otherwise be included; and (b) a provision preventing such holder or prospective holder from
making a demand for registration. 
 (o) Termination of Registration Rights. 

(1) The registration obligations of the Company pursuant to this Section 2 shall terminate with respect to any Holder
on the first date upon which all of the remaining Registrable Securities then held or issuable to such Holder (together with its Affiliates, partners, members and former partners and former members) could be sold under Rule 144 without restriction.

 (2) All registration obligations of the Company pursuant to this Section 2 shall terminate as to all Holders
three (3) years after the closing date of the Qualified IPO. 
 (3) All registration obligations of the Company pursuant to this
Section 2 shall terminate as to all Holders immediately prior to (i) any liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, or (ii) a Change of Control (as such term is
defined in the Certificate). 
  

	3.	Information Rights; No Publicity; IPO Participation Right. 

 (a) Delivery of Financial
Statements; Inspection Rights. 
 (1) The Company will furnish the following reports to each Investor holding at least 1,000,000 shares
of the Company’s Preferred Stock (as adjusted for any share splits, combinations, dividends or the like with respect to such shares) (a “Major Investor”): 

(i) as soon as practicable after the end of each fiscal year of the Company, and in any event within one hundred eighty (180) days
thereafter, a balance sheet of the Company as at the end of such fiscal year and statement of stockholders’ equity as of the end of such year, and statements of income and cash flows of the Company for such year, such year-end financial reports
to be in reasonable detail, prepared in accordance with generally accepted accounting principles (“GAAP”), which will be audited and certified by an independent public accounting firm selected by the Company unless otherwise
determined by the Board; and 

  
 -16- 

 (ii) at least thirty (30) days after the beginning of each fiscal year, an 

annual budget and forecast for such fiscal year, prepared on a quarterly basis. 

(2) The Company shall permit each Major Investor, at such Major Investor’s expense, to visit and inspect the Company’s properties, to
examine its books of account and records and to discuss the Company’s affairs, finances and accounts with its officers, all at such reasonable times as may be requested by the Major Investor. 

(3) The Company shall not be obligated under this Section 3 to provide any information that (i) it deems in good
faith to be a trade secret or similar confidential information or (ii) the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel, as advised by counsel. 

(b) Termination of Information and Inspection Covenants. The covenants set forth in Section 3(a) shall
terminate and be of no further force or effect immediately prior to the earliest to occur of (i) the closing of the Qualified IPO, (ii) the time when the Company first becomes subject to the periodic reporting requirements of Sections
12(g) or 15(d) of the 1934 Act, or 
 (iii) the consummation of a Change of Control (as such term is defined in the Certificate). 

(c) Confidentiality. Each Investor agrees, severally and not jointly, that such Investor will keep confidential and will not disclose,
divulge or use for any purpose, other than to monitor its investment in the Company, any confidential information obtained from the Company pursuant to the terms of this Agreement or otherwise, and such Investor acknowledges that it will not, unless
otherwise required by law or the rules of any national securities exchange, association or marketplace, disclose such information without the prior written consent of the Company except such information that (i) is known or becomes known to the
public in general (other than as a result of a breach of this Section 3(c) by an Investor), or (ii) is or has been independently developed or conceived by the Investor without use of the Company’s confidential
information. 
 (d) IPO Participation Right. Subject to compliance at the time with all applicable securities laws and regulations,
the Company will use commercially reasonable efforts (which shall include multiple attempts, on multiple dates, with multiple representatives of the managing underwriter(s), including oral and written communications with the most senior underwriter
employees working on the IPO) to cause the managing underwriter(s) of the IPO to provide Baker Bros., provided Baker Bros. is a Major Investor immediately prior to the IPO, on the same terms, including the price per share, and subject to the same
conditions, as are applicable to all other purchasers in the IPO, the option to purchase a number of shares of Common Stock being issued in the IPO equal to up to twenty-five percent (25%) of the total number of shares of Common Stock offered for
sale in the IPO (the “New IPO Shares”). Baker Bros. may elect to allocate such New IPO Shares among the funds which it advises in its sole discretion. 

  
 -17- 

 (e) No Publicity. The Company agrees that it will not, without the prior written consent
of Baker Bros., use in advertising, publicity or marketing communications regarding the Company’s Series B Preferred Stock financing (whether oral or written) or other public communication or filing, the Baker Bros. name or, to the
Company’s knowledge, the name of any partner or employee thereof, nor any trade name, trademark, trade device, service mark, symbol or any abbreviation, or contraction thereof owned by Baker Bros., except that the Company may make any such
disclosure if, upon the advice of counsel, there is no alternative to such disclosure because it is required by applicable law or regulation, and Baker Bros. is notified of such obligation in advance and given reasonable opportunity to minimize such
disclosure. Notwithstanding the foregoing, the Company may disclose the name of Baker Bros. in connection with the provision of any details regarding this Agreement or the Related Agreements (as defined in the Purchase Agreement) and the
transactions contemplated hereby and thereby to any of its executive officers, directors, stockholders, accountants, counsel and financial advisors with a need to know such information, provided that such recipient is notified of the foregoing
confidentiality obligations. 
  

	4.	Preemptive Rights. 

 (a) Content of Preemptive Right. Subject to the terms and
conditions specified in this Section 4 and applicable securities laws, in the event the Company proposes to offer or sell any New Securities, the Company shall first make an offering of such New Securities to each Investor
holding at least 100,000 shares of the Company’s Preferred Stock (as adjusted for any share splits, combinations, dividends or the like with respect to such shares) (a “ROFR Investor”) in accordance with
the provisions of this Section 4. 
 (b) Offer Notice. The Company shall deliver a notice, in
accordance with the provisions of Section 5(a) hereof, (the “Offer Notice”) to each of the ROFR Investors stating (i) its bona fide intention to offer such New Securities, (ii) the number of
such New Securities to be offered, and (iii) the price and terms upon which it proposes to offer such New Securities. 
 (c) Exercise
of Preemptive Right. By written notification received by the Company within ten (10) days after receipt of the Offer Notice, each of the ROFR Investors may elect to purchase or obtain, at the price and on the terms specified in the Offer
Notice, up to that portion of such New Securities which equals the proportion that the number of shares of Common Stock issuable or issued upon conversion of Preferred Stock (and any other securities convertible into, or otherwise exercisable or
exchangeable for, shares of Common Stock) then held by such ROFR Investor bears to the total number of shares of Common Stock of the Company then outstanding (assuming full conversion and exercise of all outstanding convertible and/or exercisable
securities including outstanding options and warrants and including the ungranted option pool provided for in any equity plan established by the Company and approved by the Board) and held by all securityholders of the Company. 

(d) Undersubscription. If all New Securities referred to in the Offer Notice are not elected to be fully purchased or obtained as
provided in Section 4(c), the Company may, during the one hundred fifty (150) day period following the expiration of the period provided in Section 4(c), offer, sell or agree to sell the
remaining unsubscribed portion of such New 

  
 -18- 

 
Securities (collectively, the “Refused Securities”) to any person or persons at a price not less than, and upon terms not materially more favorable to the offeree than,
those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the New Securities within such period, or if such agreement is not consummated within sixty (60) days after the end of such one hundred fifty
(150) day period, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the Investors in accordance with this Section 4. 

(e) Exempt Issuance. The preemptive right in this Section 4 shall not be applicable to the issuance or sale
of: (i) any shares issued pursuant to the Purchase Agreement; (ii) any Excluded Stock, as such term is defined in the Certificate, including any options or rights to subscribe for or purchase Excluded Stock or securities by their terms
convertible into or exchangeable for Excluded Stock or options to purchase or rights to subscribe for or purchase such convertible or exchangeable securities for Excluded Stock; (iii) any securities that, with approval of the Board, are not
offered to any existing stockholder of the Company; (iv) shares as to which the application of this Section 4 is waived by (x) Holders holding a majority of the outstanding Registrable Securities or (y) the
Board. In addition to the foregoing, the preemptive right in this Section 4 shall not be applicable with respect to any ROFR Investor in any offering of New Securities if (A) at the time of such offering, the Investor
is not an “accredited investor,” as such term is defined in Rule 501(a) of Regulation D promulgated under the Securities Act and (B) such offering of the New Securities is otherwise being offered only to accredited investors and/or Persons
other than U.S. Persons (as defined in Rule 902 under the Securities Act). 
 (f) Assignability. The preemptive right set forth in
this Section 4 may not be assigned or transferred except that such right is assignable by each ROFR Investor to any Affiliate of such ROFR Investor. 

(g) Termination. The preemptive right set forth in this Section 4 shall terminate upon the earlier of:
(i) immediately prior to the consummation of the Qualified IPO, or (ii) immediately prior to the consummation of a Change of Control (as such term is defined in the Certificate). The preemptive right set forth in this
Section 4 shall terminate with respect to any ROFR Investor who fails to purchase, in any transaction subject to this Section 4, all of such ROFR Investor’s pro rata amount of the New
Securities allocated (or, if less than such ROFR Investor’s pro rata amount is offered by the Company, such lesser amount so offered) to such ROFR Investor pursuant to this Section 4. Following any such termination,
such ROFR Investor shall no longer be deemed a “ROFR Investor” for any purpose of this Section 4. 
  

	5.	Miscellaneous. 

 (a) Notices. Any notice or other communication required or
permitted to be delivered to any party under this Agreement will be in writing and will be deemed delivered, given and received when delivered (by hand, by registered mail, by courier or express delivery service, by
e-mail or by facsimile) to the address, e-mail address or facsimile telephone number set forth beneath the name of such party below (or to such other address, e-mail address or facsimile telephone number as such party will have specified in a written notice given to the other parties hereto): 

  
 -19- 

	 	(i)	if to the Company: 

 Kodiak Sciences Inc. 

2631 Hanover Street 
 Palo Alto,
California 94304 
 Attention: Victor Perlroth 

E-mail: vperlroth@kodiaksciences.com 

with a copy (which shall not constitute notice) to: 

Jones Day 
 1755 Embarcadero
Road 
 Palo Alto, California 94303 

Attention: David B. SIkes 

Facsimile: (650) 739-3900 
  

	 	(ii)	if to an Investor: 

 To the address, e-mail address or
facsimile telephone number of such Investor indicated on such Investor’s signature page. 
 (b) Entire Agreement. This Agreement
(including the exhibits hereto) and the documents mentioned herein constitute the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede any and all prior understandings and agreements, whether
written or oral, with respect to such subject matter. 
 (c) Amendments, Waivers and Consents. Any term of this Agreement (other than
Section 3 and Section 4) may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively) only
with the written consent of the Company and the holders of a majority of the shares of Common Stock and Preferred Stock, voting together as a single class, with the Preferred Stock voting on an as-converted
into Common Stock basis. The provisions of Section 3 may be amended or waived (either generally or in a particular instance and either retroactively or prospectively) in a manner that materially decreases the rights of
Major Investors hereunder only with the written consent of the Company and the Major Investors holding a majority of the Registrable Securities that are held by all of the Major Investors. The provisions of Section 4 may be
amended or waived (either generally or in a particular instance and either retroactively or prospectively) only as set forth in Section 4 or with the written consent of the Company and the ROFR Investors holding a majority
of the Registrable Securities that are held by all of the ROFR Investors. Any amendment, termination or waiver effected in accordance with this Section 5(c) shall be binding on all parties hereto (including future
Investors), even if they do not execute such consent. No consent shall be necessary to add additional Persons as signatories to this Agreement, provided that such Persons shall hold or have acquired shares of the Company’s capital stock. 

  
 -20- 

 (d) Binding Effect; Assignment. This Agreement and any amendment or waiver affected in
accordance with Section 5(c) shall be binding upon and inure to the benefit of the personal representatives, successors and permitted assigns of the respective parties hereto. The Company shall not assign this Agreement or
any rights or obligations hereunder without the prior written consent of holders of at least a majority of the Registrable Securities held by Investors. Except with respect to the indemnified persons contemplated by
Section 2(j) who are intended third party beneficiaries of this Agreement and except as otherwise expressly provided for herein, nothing in this Agreement is intended to confer upon any party other than the parties hereto
or their respective successors and assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement. 
 (e)
Titles and Subtitles. The titles, captions and headings of this Agreement are included for ease of reference only and will be disregarded in interpreting or construing this Agreement. Unless otherwise specifically stated, all references
herein to “Sections” and “Exhibits” will mean “Sections” and “Exhibits” to this Agreement. 
 (f)
Governing Law; Dispute Resolution. This Agreement shall be governed by and construed under the laws of the State of Delaware in all respects as such laws are applied to agreements among Delaware residents entered into and performed entirely
within Delaware, without giving effect to conflict of law principles thereof. The parties agree that any action brought by either party under or in relation to this Agreement, including without limitation to interpret or enforce any provision of
this Agreement, shall be brought in, and each party agrees to and does hereby submit to the jurisdiction and venue of, any state or federal court located in the county where the Company’s principal office is located. 

(g) Severability. In the event that any provision of this Agreement, or the application thereof, becomes or is declared by a court of
competent jurisdiction to be illegal, void or unenforceable, the remainder of this Agreement shall continue in full force and effect and shall be interpreted so as reasonably to effect the intent of the parties hereto. The parties hereto shall use
their commercially reasonable efforts to replace such void or unenforceable provision of this Agreement with a valid and enforceable provision that shall achieve, to the extent possible, the economic, business and other purposes of such void or
unenforceable provision. 
 (h) Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same agreement. 
 (i) Specific Performance. The Company recognizes
that the rights of the Holders under this Agreement are unique, and, accordingly, the Holders shall, in addition to such other remedies as may be available to them at law or in equity, have the right to enforce their rights hereunder by actions for
injunctive relief and specific performance to the extent permitted by law. This Agreement is not intended to limit or abridge any rights of the Holders which may exist apart from this Agreement. 

  
 -21- 

 (j) Aggregation of Stock. All shares of Registrable Securities held or acquired by
affiliated entities or persons shall be aggregated together for the purpose of determining the availability of any rights under this Agreement. 

[Remainder of Page Intentionally Left Blank] 

  
 -22- 

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

 

			
	 COMPANY:
  

KODIAK SCIENCES INC.

		
	By:	 	 /s/ Victor Perlroth

	Name:	 	Victor Perlroth
	Title:	 	Chief Executive Officer

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

667, L.P. 
  

					
	By:	 	BAKER BROS. ADVISORS LP, management company and investment adviser to 667, L.P., pursuant to authority granted to it by Baker Biotech Capital, L.P., general partner to 667, L.P., and not as
the general partner.
			
		 		  	
	    	 	By:	  	/s/ Scott L. Lessing                                
		 	Name:	  	Scott L. Lessing
		 	Title:	  	President

 Contact information for notices hereunder: 

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

BAKER BROTHERS LIFE SCIENCES, L.P. 
  

					
	By:	 	BAKER BROS. ADVISORS LP, management company and investment adviser to Baker Brothers Life Sciences, L.P., pursuant to authority granted to it by Baker Brothers Life Sciences Capital, L.P., general partner
to Baker Brothers Life Sciences, L.P., and not as the general partner.
			
		 		  	
	    	 	By:	  	/s/ Scott L. Lessing                                
		 	Name:	  	Scott L. Lessing
			
		 	Title:	  	President

 Contact information for notices hereunder: 

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Matt Altman
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Matt Altman
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	      
	 		  	 Asia Intelligence Holdings Limited

	Print Investor’s Name	 		  	Name of the Entity
			
	      
	 		  	 /s/ Rong Lu

	Investor’s Signature	 		  	Signature
			
		 		  	 Rong Lu

		 		  	Print Name
			
		 		  	 Director

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 John Bedbrook
	 		  	 Bedbrook Survivors Trust

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ John Bedbrook
	 		  	 /s/ John Bedbrook

	Investor’s Signature	 		  	Signature
			
		 		  	 John Bedbrook

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Derek Berry
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Derek Berry
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Jack Cabala
	 		  	      

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Jack Cabala
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	      

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	
		
	Attn:	 	
	Fax:	 	
	Email:	 	

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 John K. Cabala
	 		  	      

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ John K. Cabala
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	      

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Stephen A. Charles
	 		  	      

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Stephen A. Charles
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	      

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 David Collet
	 		  	      

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ David Collet
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	      

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	
		
	Attn:	 	
	Fax:	 	
	Email:	 	

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Michelle Hocking De Geest
	 		  	      

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Michelle Hocking De Geest 
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	      

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	      
	 		  	 Francois Guy Drouin Revocable Trust Dated Feb 25, 2010

	Print Investor’s Name	 		  	Name of the Entity
			
	      
	 		  	 /s/ Francois Drouin, Trustee

	Investor’s Signature	 		  	Signature
			
		 		  	 Francois Drouin, Trustee

		 		  	Print Name
			
		 		  	      

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	
		
	Attn:	 	
	Fax:	 	
	Email:	 	

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	      
	 		  	 Jean P Drovin Revocable Trust

	Print Investor’s Name	 		  	Name of the Entity
			
	      
	 		  	 /s/ Jean Drovin

	Investor’s Signature	 		  	Signature
			
		 		  	 Jean Drovin

		 		  	Print Name
			
		 		  	 Trustee

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	
		
	Attn:	 	
	Fax:	 	
	Email:	 	

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Karl Englest
	 		  	      

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Karl Englest
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	      

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	      
	 		  	 ERNEST J. GALLO 1993 PERSONAL TRUST

	Print Investor’s Name	 		  	Name of the Entity
			
	      
	 		  	 /s/ ERNEST J. GALLO

	Investor’s Signature	 		  	Signature
			
		 		  	 ERNEST J. GALLO

		 		  	Print Name
			
		 		  	 TRUSTEE

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Michael A Fournel
	 		  	      

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Michael A Fournel
	 		  	      

	Investor’s Signature	 		  	Signature
			
		 		  	      

		 		  	Print Name
			
		 		  	      

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	      
	 		  	 GC&H Investments, LLC

	Print Investor’s Name	 		  	Name of the Entity
			
	      
	 		  	 /s/ Jim Kindler

	Investor’s Signature	 		  	Signature
			
		 		  	 Jim Kindler

		 		  	Print Name
			
		 		  	 Manager

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	  
	 		  	 Goodman Barinaga Charitable Trust dated 9/18/07

	Print Investor’s Name	 		  	Name of the Entity
			
	      
	 		  	 /s/ Corey Goodman

	Investor’s Signature	 		  	Signature
			
		 		  	 Corey Goodman

		 		  	Print Name
			
		 		  	 Managing Partner - Trustee

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Alan Grayce
	 		  	      

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Alan Grayce
	 		  	      

	Investor’s Signature	 		  	Signature
			
		 		  	      

		 		  	Print Name
			
		 		  	      

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Nahum Guzik
	 		  	      

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Nahum Guzik
	 		  	      

	Investor’s Signature	 		  	Signature
			
		 		  	      

		 		  	Print Name
			
		 		  	      

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	      
	 		  	 Ketchum Capital, LLC

	Print Investor’s Name	 		  	Name of the Entity
			
	      
	 		  	 /s/ Karl Englert

	Investor’s Signature	 		  	Signature
			
		 		  	 Karl Englert

		 		  	Print Name
			
		 		  	 Manager

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	
		
	Attn:	 	                
	Fax:	 	
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Bruce Keyt
	 		  	      

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Bruce Keyt
	 		  	      

	Investor’s Signature	 		  	Signature
			
		 		  	      

		 		  	Print Name
			
		 		  	      

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	
		
	Attn:	 	                
	Fax:	 	
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Michael Kiparsky
	 		  	      

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Michael Kiparsky
	 		  	      

	Investor’s Signature	 		  	Signature
			
		 		  	      

		 		  	Print Name
			
		 		  	      

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	
		
	Attn:	 	                
	Fax:	 	
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 [ILLEGIBLE]
	 		  	      

	Print Investor’s Name	 		  	Name of the Entity
			
	 [ILLEGIBLE]
	 		  	      

	Investor’s Signature	 		  	Signature
			
		 		  	      

		 		  	Print Name
			
		 		  	      

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	
		
	Attn:	 	                
	Fax:	 	
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 James Montazee
	 		  	      

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ James Montazee
	 		  	      

	Investor’s Signature	 		  	Signature
			
		 		  	      

		 		  	Print Name
			
		 		  	      

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

 

					
	INVESTOR:
	
	 DUSTIN A. MOSKOVITZ TTEE

DUSTIN A. MOSKOVITZ TRUST DTD 12/27/05

		
	By:	 	 /s/ Jed Clark

		 	Name:	 	Jed Clark
		 	Title:	 	Authorized Signatory

 
					
	
	Contact information for notices hereunder:
		
	Address:	 	
		
	Attn:	 	
	Fax:	 	
	Email:	 	

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	  
	 		  	 The O’Brien Family Trust

	Print Investor’s Name	 		  	Name of the Entity
			
	  
	 		  	 /s/ Eric O’Brien

	Investor’s Signature	 		  	Signature
			
		 		  	 Eric O’Brien

		 		  	Print Name
			
		 		  	 Trustee

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title.
			
	  
	 		  	 John S Osterweis, trustee for the Osterweis Receivable Trust dated 4/13/18

	Print Investor’s Name	 		  	Name of the Entity
			
	  
	 		  	 /s/ John S Osterweis

	Investor’s Signature	 		  	Signature
			
		 		  	 John S Osterweis

		 		  	Print Name
			
		 		  	 Trustee

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	  
	 		  	 PAUL AND MORCIA COOK LIVING TRUST

	Print Investor’s Name	 		  	Name of the Entity DATED 4-21-92
			
	  
	 		  	 /s/ PAUL M. COOK

	Investor’s Signature	 		  	Signature
			
		 		  	 PAUL M. COOK, TRUSTEE

		 		  	Print Name
			
		 		  	 TRUSTEE

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Paul L Beckman
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Paul L Beckman
	 		  	 /s/ Paul L Beckman/ Linda S Beckman

	Investor’s Signature	 		  	Signature
			
		 		  	 Paul L Beckman/ Linda S Beckman

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 D. Victor Perlroth
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ D. Victor Perlroth
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 MLPF&S FBO Daniel Victor Perlroth
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Victor Perlroth
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Mark G. Perlroth
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Mark G. Perlroth
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Frank Perlroth
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Frank Perlroth
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

 

					
	INVESTOR:
	
	Sarah Nicole Perlroth
		
	By:	 	 /s/ Sarah Nicole Perlroth

		 	Name:	 	Sarah Nicole Perlroth
		 	Title:	 	n/a

 
					
	
	Contact information for notices hereunder:
		
	Address:	 	
		
	Attn:	 	
	Fax:	 	
	Email:	 	

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Andrew Raab
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Andrew Raab
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Erik D. Ragatz
	 		  	 Ragatz Revocable Trust Dated 1/9/06

	Print Investor’s Name	 		  	Name of the Entity
			
	  
	 		  	 /s/ Erik D. Ragatz

	Investor’s Signature	 		  	Signature
			
		 		  	 Erik D. Ragatz

		 		  	Print Name
			
		 		  	 TRUSTEE

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	  
	 		  	 Robert L. Morse Jr. and Susan Cleary Morse Trust

	Print Investor’s Name	 		  	Name of the Entity
			
	  
	 		  	 /s/ Robert L. Morse Jr.

	Investor’s Signature	 		  	Signature
			
		 		  	 Robert L. Morse Jr.

		 		  	Print Name
			
		 		  	 Trustee

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Scott Robertson
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Scott Robertson
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Robert E. Sarafan
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Robert E. Sarafan
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	
		
	Attn:	 	
	Fax:	 	
	Email:	 	

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Thomas A.
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Thomas A.
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Marc Saiontz
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Marc Saiontz
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Steven Sanislo
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Steven Sanislo
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 John Schroer
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ John Schroer
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 R. Randolph Scott
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ R. Randolph Scott
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Gregory A. Sissel
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Gregory A. Sissel
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	  
	 		  	 Smith Family Trust

	Print Investor’s Name	 		  	Name of the Entity
			
	  
	 		  	 /s/ Fred Smith

	Investor’s Signature	 		  	Signature
			
		 		  	 Fred Smith

		 		  	Print Name
			
		 		  	 Trustee

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	
		
	Attn:	 	
	Fax:	 	
	Email:	 	

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 David Stack
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ David Stack
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	  
	 		  	 Stanford-StartX LLC

	Print Investor’s Name	 		  	Name of the Entity
			
	  
	 		  	 /s/ Sabrina Liang

	Investor’s Signature	 		  	Signature
			
		 		  	 Sabrina Liang

		 		  	Print Name
			
		 		  	 Director, School & Department Funds

		 		  	Title 

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	     
	 		  	 Steep Rock Capital LTD

	Print Investor’s Name	 		  	Name of the Entity
			
	  
	 		  	 /s/ Paul Swigart

	Investor’s Signature	 		  	Signature
			
		 		  	 Paul Swigart

		 		  	Print Name
			
		 		  	 Director

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written: 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Andrew Stephens
	 		  	 The Stephens Family Trust dated June 13, 2006

	Print Investor’s Name	 		  	Name of the Entity    
			
	 /s/ Andrew Stephens
	 		  	 /s/ Andrew Stephens

	Investor’s Signature	 		  	Signature
			
		 		  	 Andrew Stephens

		 		  	Print Name
			
		 		  	 Trustee

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	
		
	Attn:	 	
	Fax:	 	
	Email:	 	

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	      
	 		  	 The Cheng Family Trust

	Print Investor’s Name	 		  	Name of the Entity
			
	      
	 		  	 /s/ Wallace Cheng

	Investor’s Signature	 		  	Signature
			
		 		  	 Wallace Cheng and Gretchen Cheng, As Trustees of the Cheng Family Trust dated March 7, 2013

		 		  	Print Name
			
		 		  	 Trustee

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

  
 75 

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
	      
	 		  	 Franklin H. Top, Jr. Revocable Inter Vivos Trust, dated 12/3/1991

	Print Investor’s Name	 		  	Name of the Entity
			
	      
	 		  	 /s/ Franklin H. Top, Jr.

	Investor’s Signature	 		  	Signature
			
		 		  	 Franklin H. Top, Jr.

		 		  	Print Name
			
		 		  	 Trustee

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

  
 76 

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
	  

     
	 		  	  
 Lois E. Top Revocable Inter Vivos
Trust, dated December 3, 1991

	Print Investor’s Name	 		  	Name of the Entity
			
	      
	 		  	 /s/ Lois E. Top

	Investor’s Signature	 		  	Signature
			
		 		  	 Lois E. Top

		 		  	Print Name
			
		 		  	 Trustee

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

  
 77 

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Walt Ordemann 
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Walt Ordemann 
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

  
 78 

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Trevor Watt
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Trevor Watt 
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

  
 79 

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Steven Winch
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Steven Winch
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

  

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Peter Van Vlasselaer
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Peter Van Vlasselaer
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

  

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Grant Yonehiro
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Grant Yonehiro
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

  

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Fan Zhang
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Fan Zhang
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

  

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Tony Zheng
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Tony Zheng
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

  

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	      
	 		  	 Masaya LLC

	Print Investor’s Name	 		  	Name of the Entity
			
	      
	 		  	 /s/ Carlos Gonzalez 

	Investor’s Signature	 		  	Signature
			
		 		  	 Carlos Gonzalez

		 		  	Print Name
			
		 		  	 Managing Member

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

  

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	      
	 		  	 Macro Biotech LLC

	Print Investor’s Name	 		  	Name of the Entity
			
	      
	 		  	 /s/ Carlos Gonzalez 

	Investor’s Signature	 		  	Signature
			
		 		  	 Carlos Gonzalez

		 		  	Print Name
			
		 		  	 Manager

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

  

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	      
	 		  	 SEM Biopharm, LLC

	Print Investor’s Name	 		  	Name of the Entity
			
	      
	 		  	 /s/ Rafael Urquia II

	Investor’s Signature	 		  	Signature
			
		 		  	 Rafael Urquia II

		 		  	Print Name
			
		 		  	 Manager

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

  

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Ron Glickman
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Ron Glickman 
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

  
 88 

 KODIAK SCIENCES INC. 

AMENDMENT NO. 1 TO 

INVESTORS’ RIGHTS AGREEMENT 

This Amendment No. 1 (this “Amendment”) to the Investors’ Rights Agreement, dated as of September 8,
2015 (the “Rights Agreement”), by and among Kodiak Sciences Inc., a Delaware corporation (the “Company”), and each of the stockholders of the Company that has delivered a signature page to the Rights
Agreement (the “Investors”), is made and entered into effective as of February 22, 2018 by and among the Company and the Investors. Capitalized terms used in this Amendment that are not otherwise defined herein shall
have the respective meanings assigned to them in the Rights Agreement. 
 RECITALS 

WHEREAS, pursuant to Section 5(c) of the Rights Agreement, any provision thereof (other than Sections 3 and 4) may be amended or
waived with the written consent of the Company and the holders of a majority in interest of the shares of the Company’s Common Stock and Preferred Stock (on an as-converted basis); and 

WHEREAS, the undersigned desire to amend and grant certain waivers under the Rights Agreement. 

NOW, THEREFORE, in consideration of the promises and mutual covenants, terms and conditions set forth herein, the undersigned hereby
agree as follows: 
 AGREEMENT 

1. Amendment of Section 1. The definition of “Conversion Securities” in Section 1 of
the Rights Agreement is hereby amended and restated in its entirety to read as follows: 
 “Conversion Securities”
means (i) any Common Stock held by an Investor; (ii) any Common Stock issuable or issued upon conversion of the Preferred Stock now held or hereafter acquired by an Investor or as a dividend or other distribution with respect to, in
exchange for, or in replacement of the Preferred Stock now held or hereafter acquired by an Investor; (iii) any Common Stock issuable or issued upon exercise of any warrants to purchase Common Stock (or exercise and conversion of warrants to
purchase Preferred Stock) held by an Investor or as a distribution with respect to, in exchange for, or replacement of any warrants to purchase Common Stock (or Preferred Stock) held by an Investor; (iv) any Common Stock issuable upon
conversion of any Notes (as defined in that certain Convertible Note Purchase Agreement, dated as of February 2, 2018, among the Company, the Purchasers from time to time party thereto and, solely with respect to Section 2.3 thereof, Baker
Bros. Advisors L.P. (the “Note Purchase Agreement”)) pursuant to Sections 5.1 or 5.2 of the Note Purchase Agreement and any Other Financing Securities (or Common Stock issuable upon the conversion thereof) issuable
pursuant to Section 5.4 of the Note Purchase Agreement; and (v) any Common Stock issued as a dividend or other distribution with respect to, in exchange for, or in replacement of any of the Common Stock that constitutes Conversion
Securities pursuant to (i), (ii), (iii) and (iv) above. 

 2. Waiver of Section 2(n). The undersigned hereby waive, on behalf of
themselves and all Investors, the application of Section 2(n) of the Rights Agreement with respect to the entry by the Company into any registration rights agreement pursuant to Section 8.3 of the Note Purchase Agreement. 

3. Additional Rights Agreement Parties. Notwithstanding anything to the contrary in the Rights Agreement, the undersigned hereby
consent to the joinder of any holder of Notes to the Rights Agreement upon such holder’s delivery of a counterpart signature page thereto. 

4. Effect. Except as expressly set forth herein, all other provisions of the Rights Agreement shall remain in full force and effect.
This Amendment shall be deemed incorporated into and made a part of the Rights Agreement. 
 5. Governing Law. This Amendment shall
be governed in all respects by the internal laws of the State of Delaware, without regard to conflicts of law provisions of the State of Delaware or any other state. 

6. Entire Agreement. This Amendment, the Rights Agreement, and to the extent applicable, the Note Purchase Agreement, constitute the
full and entire understanding and agreement between the parties with regard to the subjects hereof and thereof. No party shall be liable or bound to any other party in any manner with regard to the subjects hereof or thereof by any warranties,
representations or covenants except as specifically set forth herein or therein. 
 7. Severability. If any provision of this
Amendment becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, portions of such provision, or such provision in its entirety, to the extent necessary, shall be severed from this Amendment, and such court
will replace such illegal, void or unenforceable provision of this Amendment with a valid and enforceable provision that will achieve, to the extent possible, the same economic, business and other purposes of the illegal, void or unenforceable
provision. The balance of this Amendment shall remain enforceable in accordance with its terms. 
 8. Counterparts; Facsimile. This
Amendment may be executed in any number of counterparts, each of which shall be an original, and all of which together shall constitute one instrument. Executed signatures transmitted via facsimile or PDF will be accepted and considered duly
executed. 
 (signature page follows) 

  
 -2- 

 IN WITNESS WHEREOF, the parties have caused this Amendment to be duly executed and delivered by
their proper and duly authorized officers as of the date and year first written above. 
  

			
	COMPANY:
	
	KODIAK SCIENCES INC.
		
	By:	 	/s/ John Borgeson
		 	John Borgeson 
		 	Chief Financial Officer

  
 (Signature Page to
Amendment No. 1 to Investors’ Rights Agreement) 

 IN WITNESS WHEREOF, the parties have caused this Amendment to be duly executed and delivered by
their proper and duly authorized officers as of the date and year first written above. 
 STOCKHOLDER: 

667, L.P. 
 By: BAKER BROS. ADVISORS LP, management
company and investment adviser to 667, L.P., pursuant to authority granted to it by Baker Biotech Capital, L.P., general partner to 667, L.P., and not as the general partner. 
  

			
	By:	 	/s/ Scott L. Lessing
	Scott L. Lessing
	President

 BAKER BROTHERS LIFE SCIENCES, L.P. 

By: BAKER BROS. ADVISORS LP, management company and investment adviser to Baker Brothers Life Sciences, L.P., pursuant to authority granted to it by
Baker Brothers Life Sciences Capital, L.P., general partner to Baker Brothers Life Sciences, L.P., and not as the general partner. 
  

			
	By:	 	/s/ Scott L. Lessing
	Scott L. Lessing
	President

  
 (Signature Page to
Amendment No. 1 to Investors’ Rights Agreement) 

 IN WITNESS WHEREOF, the parties have caused this Amendment to be duly executed and delivered by
their proper and duly authorized officers as of the date and year first written above. 
  

			
	STOCKHOLDER:
		
		 	Victor Perlroth, M.D.
		 	Shareholder

  

			
		 	/s/ Victor Perlroth 
		 	Signature

  

			
		 	 
		 	 Print name and title, if signing on behalf of an entity

  
 (Signature Page to
Amendment No. 1 to Investors’ Rights Agreement) 

 IN WITNESS WHEREOF, the parties have caused this Amendment to be duly executed and delivered by
their proper and duly authorized officers as of the date and year first written above. 
  

	
	STOCKHOLDER:
	
	Sigma Emerging Markets Ltd.
	
	/s/ Rafael Urquia
	Signature

 
	
	
	   

	Rafael Urquia II, Secretary

  
 (Signature Page to
Amendment No. 1 to Investors’ Rights Agreement) 

 IN WITNESS WHEREOF, the parties have caused this Amendment to be duly executed and delivered by
their proper and duly authorized officers as of the date and year first written above. 
  

	
	STOCKHOLDER:
	
	Dustin A. Moskovitz Trust DTD 12/27/05
	
	/s/ Jed Clark
	Signature

 
	
	
	Jed Clark; Authorized Signatory
	Print name and title, if signing on behalf of an entity

  
 (Signature Page to
Amendment No. 1 to Investors’ Rights Agreement) 

 IN WITNESS WHEREOF, the parties have caused this Amendment to be duly executed and delivered by
their proper and duly authorized officers as of the date and year first written above. 
  

	
	STOCKHOLDER:
	
	Macro Continental, Inc. 
	
	/s/ Carlos A. Gonzalez May 
	Signature

 
	
	
	Carlos A. Gonzalez May; Director 
	Print name and title, if signing on behalf of an entity

  
 (Signature Page to
Amendment No. 1 to Investors’ Rights Agreement)EX-10.1

 Exhibit 10.1 

KODIAK SCIENCES INC. 

INDEMNIFICATION AGREEMENT 

This Indemnification Agreement (this “Agreement”) is dated as of ____________, and is between Kodiak Sciences Inc., a
Delaware corporation (the “Company”), and ____________ (“Indemnitee”). 
 RECITALS

 A. Indemnitee’s service to the Company substantially benefits the Company. 

B. Individuals are reluctant to serve as directors or officers of corporations or in certain other capacities unless they are provided with
adequate protection through insurance or indemnification against the risks of claims and actions against them arising out of such service. 

C. Indemnitee does not regard the protection currently provided by applicable law, the Company’s governing documents and any insurance as
adequate under the present circumstances, and Indemnitee may not be willing to serve as a director or officer without additional protection. 

D. In order to induce Indemnitee to continue to provide services to the Company, it is reasonable, prudent and necessary for the Company to
contractually obligate itself to indemnify, and to advance expenses on behalf of, Indemnitee as permitted by applicable law. 
 E. This
Agreement is a supplement to and in furtherance of the indemnification provided in the Company’s certificate of incorporation and bylaws, and any resolutions adopted pursuant thereto, and this Agreement shall not be deemed a substitute
therefor, nor shall this Agreement be deemed to limit, diminish or abrogate any rights of Indemnitee thereunder. 
 The parties therefore
agree as follows: 
 1. Definitions. 

(a) A “Change in Control” shall be deemed to occur upon the earliest to occur after the date of this Agreement of any
of the following events: 
 (i) Acquisition of Stock by Third Party. Any Person (as defined below) becomes the Beneficial Owner (as
defined below), directly or indirectly, of securities of the Company representing fifteen percent (15%) or more of the combined voting power of the Company’s then outstanding securities; 

(ii) Change in Board Composition. During any period of two consecutive years (not including any period prior to the execution of this
Agreement), individuals who at the beginning of such period constitute the Company’s board of directors, and any new directors (other than a director designated by a person who has entered into an agreement with the Company to effect a
transaction described in Sections 1(a)(i), 1(a)(iii) or 1(a)(iv)) whose election by the board of directors 

 
or nomination for election by the Company’s stockholders was approved by a vote of at least two-thirds of the directors then still in office who
either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute at least a majority of the members of the Company’s board of directors; 

(iii) Corporate Transactions. The effective date of a merger or consolidation of the Company with any other entity, other than a
merger or consolidation which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of
the surviving entity) more than 50% of the combined voting power of the voting securities of the surviving entity outstanding immediately after such merger or consolidation and with the power to elect at least a majority of the board of directors or
other governing body of such surviving entity; 
 (iv) Liquidation. The approval by the stockholders of the Company of a complete
liquidation of the Company or an agreement for the sale or disposition by the Company of all or substantially all of the Company’s assets; and 

(v) Other Events. Any other event of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of
Regulation 14A (or in response to any similar item on any similar schedule or form) promulgated under the Securities Exchange Act of 1934, as amended, whether or not the Company is then subject to such reporting requirement, except the
completion of the Company’s initial public offering shall not be considered a Change in Control. 
 For purposes of this
Section 1(a), the following terms shall have the following meanings: 
 (1) “Person” shall have the meaning as
set forth in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended; provided, however, that “Person” shall exclude (i) the Company, (ii) any trustee or other fiduciary holding
securities under an employee benefit plan of the Company, and (iii) any corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company. 

(2) “Beneficial Owner” shall have the meaning given to such term in
Rule 13d-3 under the Securities Exchange Act of 1934, as amended; provided, however, that “Beneficial Owner” shall exclude any Person otherwise becoming a Beneficial Owner
by reason of (i) the stockholders of the Company approving a merger of the Company with another entity or (ii) the Company’s board of directors approving a sale of securities by the Company to such Person. 

(b) “Corporate Status” describes the status of a person who is or was a director, trustee, general partner, managing
member, officer, employee, agent or fiduciary of the Company or any other Enterprise. 
 (c) “DGCL” means the
General Corporation Law of the State of Delaware. 
 (d) “Disinterested Director” means a director of the Company
who is not and was not a party to the Proceeding in respect of which indemnification is sought by Indemnitee. 

  
 -2- 

 (e) “Enterprise” means the Company and any other corporation,
partnership, limited liability company, joint venture, trust, employee benefit plan or other enterprise of which Indemnitee is or was serving at the request of the Company as a director, trustee, general partner, managing member, officer, employee,
agent or fiduciary. 
 (f) “Expenses” include all reasonable and actually incurred attorneys’ fees, retainers,
court costs, transcript costs, fees and costs of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other disbursements or expenses of the types
customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, or otherwise participating in, a Proceeding. Expenses also include (i) Expenses incurred in
connection with any appeal resulting from any Proceeding, including without limitation the premium, security for, and other costs relating to any cost bond, supersedeas bond or other appeal bond or their equivalent, and (ii) for purposes of
Section 12(d), Expenses incurred by Indemnitee in connection with the interpretation, enforcement or defense of Indemnitee’s rights under this Agreement or under any directors’ and officers’ liability insurance policies
maintained by the Company. Expenses, however, shall not include amounts paid in settlement by Indemnitee or the amount of judgments or fines against Indemnitee. 

(g) “Independent Counsel” means a law firm, or a partner or member of a law firm, that is experienced in matters of
corporation law and neither presently is, nor in the past five years has been, retained to represent (i) the Company or Indemnitee in any matter material to either such party (other than as Independent Counsel with respect to matters concerning
Indemnitee under this Agreement, or other indemnitees under similar indemnification agreements), or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term
“Independent Counsel” shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action
to determine Indemnitee’s rights under this Agreement. 
 (h) “Proceeding” means any threatened, pending or
completed action, suit, arbitration, mediation, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or proceeding, whether brought in the right of the Company or otherwise and whether of a civil, criminal,
administrative or investigative nature, including any appeal therefrom and including without limitation any such Proceeding pending as of the date of this Agreement, in which Indemnitee was, is or will be involved as a party, a potential party, a non-party witness or otherwise by reason of (i) the fact that Indemnitee is or was a director or officer of the Company, (ii) any action taken by Indemnitee or any action or inaction on Indemnitee’s
part while acting as a director or officer of the Company, or (iii) the fact that he or she is or was serving at the request of the Company as a director, trustee, general partner, managing member, officer, employee, agent or fiduciary of the
Company or any other Enterprise, in each case whether or not serving in such capacity at the time any liability or Expense is incurred for which indemnification or advancement of expenses can be provided under this Agreement. 

  
 -3- 

 (i) Reference to “other enterprises” shall include employee benefit
plans; references to “fines” shall include any excise taxes assessed on a person with respect to any employee benefit plan; references to “serving at the request of the Company” shall include any service as a
director, officer, employee or agent of the Company which imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit plan, its participants or beneficiaries; and a person who acted in
good faith and in a manner he or she reasonably believed to be in the best interests of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner “not opposed to the best interests of the
Company” as referred to in this Agreement. 
 2. Indemnity in Third-Party Proceedings. The Company shall indemnify
Indemnitee in accordance with the provisions of this Section 2 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its
favor. Pursuant to this Section 2, Indemnitee shall be indemnified to the fullest extent permitted by applicable law against all Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by Indemnitee or on his
or her behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company and, with respect to
any criminal action or proceeding, had no reasonable cause to believe that his or her conduct was unlawful. 
 3. Indemnity in
Proceedings by or in the Right of the Company. The Company shall indemnify Indemnitee in accordance with the provisions of this Section 3 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding by or in
the right of the Company to procure a judgment in its favor. Pursuant to this Section 3, Indemnitee shall be indemnified to the fullest extent permitted by applicable law against all Expenses actually and reasonably incurred by Indemnitee or on
Indemnitee’s behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company. No
indemnification for Expenses shall be made under this Section 3 in respect of any claim, issue or matter as to which Indemnitee shall have been adjudged by a court of competent jurisdiction to be liable to the Company, unless and only to the
extent that the Delaware Court of Chancery or any court in which the Proceeding was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and
reasonably entitled to indemnification for such expenses as the Delaware Court of Chancery or such other court shall deem proper. 
 4.
Indemnification for Expenses of a Party Who is Wholly or Partly Successful. To the extent that Indemnitee is a party to or a participant in and is successful (on the merits or otherwise) in defense of any Proceeding or any claim, issue or
matter therein, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee’s behalf in connection therewith. For purposes of this section, the termination of any claim, issue or
matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter. 

5. Indemnification for Expenses of a Witness. To the extent that Indemnitee is, by reason of his or her Corporate Status, a witness in
any Proceeding to which Indemnitee is not a party, Indemnitee shall be indemnified to the extent permitted by applicable law against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee’s behalf in connection therewith.

  
 -4- 

 6. Additional Indemnification. 

(a) Notwithstanding any limitation in Sections 2, 3 or 4, the Company shall indemnify Indemnitee to the fullest extent permitted by
applicable law if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding (including a Proceeding by or in the right of the Company to procure a judgment in its favor) against all Expenses, judgments, fines and
amounts paid in settlement actually and reasonably incurred by Indemnitee or on his or her behalf in connection with the Proceeding or any claim, issue or matter therein. 

(b) For purposes of Section 6(a), the meaning of the phrase “to the fullest extent permitted by applicable law”
shall include, but not be limited to: 
 (i) the fullest extent permitted by the provision of the DGCL that authorizes or contemplates
additional indemnification by agreement, or the corresponding provision of any amendment to or replacement of the DGCL; and 
 (ii) the
fullest extent authorized or permitted by any amendments to or replacements of the DGCL adopted after the date of this Agreement that increase the extent to which a corporation may indemnify its officers and directors. 

7. Exclusions. Notwithstanding any provision in this Agreement, the Company shall not be obligated under this Agreement to make any
indemnity in connection with any Proceeding (or any part of any Proceeding): 
 (a) for which payment has actually been made to or on behalf
of Indemnitee under any statute, insurance policy, indemnity provision, vote or otherwise, except with respect to any excess beyond the amount paid; 

(b) for an accounting or disgorgement of profits pursuant to Section 16(b) of the Securities Exchange Act of 1934, as amended, or similar
provisions of federal, state or local statutory law or common law, if Indemnitee is held liable therefor (including pursuant to any settlement arrangements); 

(c) for any reimbursement of the Company by Indemnitee of any bonus or other incentive-based or equity-based compensation or of any profits
realized by Indemnitee from the sale of securities of the Company, as required in each case under the Securities Exchange Act of 1934, as amended (including any such reimbursements that arise from an accounting restatement of the Company pursuant to
Section 304 of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”), or the payment to the Company of profits arising from the purchase and sale by Indemnitee of securities in violation of Section 306 of the
Sarbanes-Oxley Act), if Indemnitee is held liable therefor (including pursuant to any settlement arrangements); 
 (d) initiated by
Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees, agents or other indemnitees, unless (i) the Company’s board of directors authorized the
Proceeding (or the relevant part of the Proceeding) prior to its initiation, (ii) the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law, (iii) otherwise
authorized in Section 12 or (iv) otherwise required by applicable law; or 

  
 -5- 

 (e) if prohibited by applicable law. 

8. Advances of Expenses. The Company shall advance the Expenses incurred by Indemnitee in connection with any Proceeding prior to its
final disposition, and such advancement shall be made as soon as reasonably practicable, but in any event no later than 90 days, after the receipt by the Company of a written statement or statements requesting such advances from time to time (which
shall include invoices received by Indemnitee in connection with such Expenses but, in the case of invoices in connection with legal services, any references to legal work performed or to expenditure made that would cause Indemnitee to waive any
privilege accorded by applicable law shall not be included with the invoice). Advances shall be unsecured and interest free and made without regard to Indemnitee’s ability to repay such advances. Indemnitee hereby undertakes to repay any
advance to the extent that it is ultimately determined that Indemnitee is not entitled to be indemnified by the Company, and no other form of undertaking shall be required other than the execution of this Agreement. This Section 8 shall not
apply to the extent advancement is prohibited by law and shall not apply to any Proceeding (or any part of any Proceeding) for which indemnity is not permitted under this Agreement, but shall apply to any Proceeding (or any part of any Proceeding)
referenced in Section 7(b) or 7(c) prior to a determination that Indemnitee is not entitled to be indemnified by the Company. 
 9.
Procedures for Notification and Defense of Claim. 
 (a) Indemnitee shall notify the Company in writing of any matter with respect to
which Indemnitee intends to seek indemnification or advancement of Expenses as soon as reasonably practicable following the receipt by Indemnitee of notice thereof. The written notification to the Company shall include, in reasonable detail, a
description of the nature of the Proceeding and the facts underlying the Proceeding. The failure by Indemnitee to notify the Company will not relieve the Company from any liability which it may have to Indemnitee hereunder or otherwise than under
this Agreement, and any delay in so notifying the Company shall not constitute a waiver by Indemnitee of any rights, except to the extent that such failure or delay materially prejudices the Company. 

(b) If, at the time of the receipt of a notice of a Proceeding pursuant to the terms hereof, the Company has directors’ and
officers’ liability insurance in effect that may be applicable to the Proceeding, the Company shall give prompt notice of the commencement of the Proceeding to the insurers in accordance with the procedures set forth in the applicable policies.
The Company shall thereafter take all commercially-reasonable action to cause such insurers to pay, on behalf of Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of such policies. 

(c) In the event the Company may be obligated to make any indemnity in connection with a Proceeding, the Company shall be entitled to assume
the defense of such Proceeding with counsel approved by Indemnitee, which approval shall not be unreasonably withheld, conditioned or delayed, upon the delivery to Indemnitee of written notice of its election to do so. After delivery of such notice,
approval of such counsel by Indemnitee and the retention of such counsel by the 

  
 -6- 

 
Company, the Company will not be liable to Indemnitee for any fees or expenses of counsel subsequently incurred by Indemnitee with respect to the same Proceeding. Notwithstanding the
Company’s assumption of the defense of any such Proceeding, the Company shall be obligated to pay the fees and expenses of Indemnitee’s separate counsel to the extent (i) the employment of separate counsel by Indemnitee is authorized
by the Company, (ii) counsel for the Company or Indemnitee shall have reasonably concluded that there is a conflict of interest between the Company and Indemnitee in the conduct of any such defense such that Indemnitee needs to be separately
represented, (iii) the Company is not financially or legally able to perform its indemnification obligations, or (iv) the Company shall not have retained, or shall not continue to retain, counsel to defend such Proceeding. Regardless of
any provision in this Agreement, Indemnitee shall have the right to employ counsel in any Proceeding at Indemnitee’s personal expense. The Company shall not be entitled, without the consent of Indemnitee, to assume the defense of any claim
brought by or in the right of the Company. 
 (d) Indemnitee shall give the Company such information and cooperation in connection with the
Proceeding as may be reasonably appropriate. 
 (e) The Company shall not be liable to indemnify Indemnitee for any settlement of any
Proceeding (or any part thereof) without the Company’s prior written consent, which shall not be unreasonably withheld, conditioned or delayed. 

(f) The Company shall not settle any Proceeding (or any part thereof) in a manner that imposes any penalty or liability on Indemnitee without
Indemnitee’s prior written consent, which shall not be unreasonably withheld, conditioned or delayed. 
 10. Procedures upon
Application for Indemnification. 
 (a) To obtain indemnification, Indemnitee shall submit to the Company a written request, including
therein or therewith such documentation and information as is reasonably available to Indemnitee and as is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification following the final disposition of the
Proceeding. The Company shall, as soon as reasonably practicable after receipt of such a request for indemnification, advise the board of directors that Indemnitee has requested indemnification. Any delay in providing the request will not relieve
the Company from its obligations under this Agreement, except to the extent such failure is prejudicial. 
 (b) Upon written request by
Indemnitee for indemnification pursuant to Section 10(a), a determination with respect to Indemnitee’s entitlement thereto shall be made in the specific case (i) if a Change in Control shall have occurred, by Independent Counsel in a
written opinion to the Company’s board of directors, a copy of which shall be delivered to Indemnitee or (ii) if a Change in Control shall not have occurred, (A) by a majority vote of the Disinterested Directors, even though less than
a quorum of the Company’s board of directors, (B) by a committee of Disinterested Directors designated by a majority vote of the Disinterested Directors, even though less than a quorum of the Company’s board of directors, (C) if
there are no such Disinterested Directors or, if such Disinterested Directors so direct, by Independent Counsel in a written opinion to the Company’s board of directors, a copy of which shall be delivered to Indemnitee or (D) if so
directed 

  
 -7- 

 
by the Company’s board of directors, by the stockholders of the Company. If it is determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within thirty
days after such determination. Indemnitee shall cooperate with the person, persons or entity making the determination with respect to Indemnitee’s entitlement to indemnification, including providing to such person, persons or entity upon
reasonable advance request any documentation or information that is not privileged or otherwise protected from disclosure and that is reasonably available to Indemnitee and reasonably necessary to such determination. Any costs or expenses (including
attorneys’ fees and disbursements) actually and reasonably incurred by Indemnitee in so cooperating with the person, persons or entity making such determination shall be borne by the Company, to the extent permitted by applicable law. 

(c) In the event the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 10(b), the
Independent Counsel shall be selected as provided in this Section 10(c). If a Change in Control shall not have occurred, the Independent Counsel shall be selected by the Company’s board of directors, and the Company shall give written
notice to Indemnitee advising him or her of the identity of the Independent Counsel so selected. If a Change in Control shall have occurred, the Independent Counsel shall be selected by Indemnitee (unless Indemnitee shall request that such selection
be made by the Company’s board of directors, in which event the preceding sentence shall apply), and Indemnitee shall give written notice to the Company advising it of the identity of the Independent Counsel so selected. In either event,
Indemnitee or the Company, as the case may be, may, within ten days after such written notice of selection shall have been given, deliver to the Company or to Indemnitee, as the case may be, a written objection to such selection; provided,
however, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of “Independent Counsel” as defined in Section 1 of this Agreement, and the
objection shall set forth with particularity the factual basis of such assertion. Absent a proper and timely objection, the person so selected shall act as Independent Counsel. If such written objection is so made and substantiated, the Independent
Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn or a court has determined that such objection is without merit. If, within 20 days after the later of (i) submission by Indemnitee of a
written request for indemnification pursuant to Section 10(a) hereof and (ii) the final disposition of the Proceeding, the parties have not agreed upon an Independent Counsel, either the Company or Indemnitee may petition the Delaware
Court of Chancery for resolution of any objection which shall have been made by the Company or Indemnitee to the other’s selection of Independent Counsel and for the appointment as Independent Counsel of a person selected by the court or by
such other person as the court shall designate, and the person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under Section 10(b) hereof. Upon the due commencement of any judicial
proceeding or arbitration pursuant to Section 12(a) of this Agreement, the Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then
prevailing). 
 (d) The Company agrees to pay the reasonable fees and expenses of any Independent Counsel. 

  
 -8- 

 11. Presumptions and Effect of Certain Proceedings. 

(a) In making a determination with respect to entitlement to indemnification hereunder, the person, persons or entity making such
determination shall, to the fullest extent not prohibited by law, presume that Indemnitee is entitled to indemnification under this Agreement, and the Company shall, to the fullest extent not prohibited by law, have the burden of proof to overcome
that presumption by clear and convincing evidence. 
 (b) The termination of any Proceeding or of any claim, issue or matter therein, by
judgment, order, settlement or conviction, or upon a plea of nolo contendere or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or
create a presumption that Indemnitee did not act in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had
reasonable cause to believe that his or her conduct was unlawful. 
 (c) For purposes of any determination of good faith, Indemnitee shall
be deemed to have acted in good faith to the extent Indemnitee relied in good faith on (i) the records or books of account of the Enterprise, including financial statements, (ii) information supplied to Indemnitee by the officers of the
Enterprise in the course of their duties, (iii) the advice of legal counsel for the Enterprise or its board of directors or counsel selected by any committee of the board of directors or (iv) information or records given or reports made to
the Enterprise by an independent certified public accountant, an appraiser, investment banker or other expert selected with reasonable care by the Enterprise or its board of directors or any committee of the board of directors. The provisions of
this Section 11(c) shall not be deemed to be exclusive or to limit in any way the other circumstances in which Indemnitee may be deemed to have met any applicable standard of conduct. 

(d) Neither the knowledge, actions nor failure to act of any other director, officer, agent or employee of the Enterprise shall be imputed to
Indemnitee for purposes of determining the right to indemnification under this Agreement. 
 12. Remedies of Indemnitee. 

(a) Subject to Section 12(e), in the event that (i) a determination is made pursuant to Section 10 of this Agreement that
Indemnitee is not entitled to indemnification under this Agreement, (ii) advancement of Expenses is not timely made pursuant to Section 8 or 12(d) of this Agreement, (iii) no determination of entitlement to indemnification shall have
been made pursuant to Section 10 of this Agreement within 90 days after the later of the receipt by the Company of the request for indemnification or the final disposition of the Proceeding, (iv) payment of indemnification pursuant to this
Agreement is not made (A) within thirty days after a determination has been made that Indemnitee is entitled to indemnification or (B) with respect to indemnification pursuant to Sections 4, 5 and 12(d) of this Agreement, within
thirty days after receipt by the Company of a written request therefor, or (v) the Company or any other person or entity takes or threatens to take any action to declare this Agreement void or unenforceable, or institutes any litigation or
other action or proceeding designed to deny, or to recover from, Indemnitee the benefits provided or intended to be provided to Indemnitee hereunder, Indemnitee shall be entitled to an adjudication by the Delaware Court of Chancery of his or her
entitlement to such indemnification or advancement of Expenses. Alternatively, Indemnitee, at his or her option, may seek an award in arbitration with respect to his or 

  
 -9- 

 
her entitlement to such indemnification or advancement of Expenses, to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of the American Arbitration Association.
Indemnitee shall commence such proceeding seeking an adjudication or an award in arbitration within 180 days following the date on which Indemnitee first has the right to commence such proceeding pursuant to this Section 12(a). The Company
shall not oppose Indemnitee’s right to seek any such adjudication or award in arbitration in accordance with this Agreement. 
 (b)
Neither (i) the failure of the Company, its board of directors, any committee or subgroup of the board of directors, Independent Counsel or stockholders to have made a determination that indemnification of Indemnitee is proper in the
circumstances because Indemnitee has met the applicable standard of conduct, nor (ii) an actual determination by the Company, its board of directors, any committee or subgroup of the board of directors, Independent Counsel or stockholders that
Indemnitee has not met the applicable standard of conduct, shall create a presumption that Indemnitee has or has not met the applicable standard of conduct. In the event that a determination shall have been made pursuant to Section 10 of this
Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to this Section 12 shall be conducted in all respects as a de novo trial, or arbitration, on the merits, and Indemnitee
shall not be prejudiced by reason of that adverse determination. In any judicial proceeding or arbitration commenced pursuant to this Section 12, the Company shall, to the fullest extent not prohibited by law, have the burden of proving
Indemnitee is not entitled to indemnification or advancement of Expenses, as the case may be, by clear and convincing evidence. 
 (c) To
the fullest extent not prohibited by law, the Company shall be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this Section 12 that the procedures and presumptions of this Agreement are not valid,
binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement. If a determination shall have been made pursuant to Section 10 of this Agreement that
Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this Section 12, absent (i) a misstatement by Indemnitee of a material fact, or an
omission of a material fact necessary to make Indemnitee’s statements not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law. 

(d) To the extent not prohibited by law, the Company shall indemnify Indemnitee against all Expenses that are incurred by Indemnitee in
connection with any action for indemnification or advancement of Expenses from the Company under this Agreement or under any directors’ and officers’ liability insurance policies maintained by the Company to the extent Indemnitee is
successful in such action, and, if requested by Indemnitee, shall (as soon as reasonably practicable, but in any event no later than 90 days, after receipt by the Company of a written request therefor) advance such Expenses to Indemnitee, subject to
the provisions of Section 8. 
 (e) Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement to
indemnification shall be required to be made prior to the final disposition of the Proceeding. 

  
 -10- 

 13. Contribution. To the fullest extent permissible under applicable law, if the
indemnification provided for in this Agreement is unavailable to Indemnitee, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amounts incurred by Indemnitee, whether for Expenses, judgments, fines or amounts paid or to be
paid in settlement, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to reflect (i) the
relative benefits received by the Company and Indemnitee as a result of the events and transactions giving rise to such Proceeding; and (ii) the relative fault of Indemnitee and the Company (and its other directors, officers, employees and
agents) in connection with such events and transactions. 
 14. Non-exclusivity. The rights
of indemnification and to receive advancement of Expenses as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Company’s certificate of
incorporation or bylaws, any agreement, a vote of stockholders or a resolution of directors, or otherwise. To the extent that a change in Delaware law, whether by statute or judicial decision, permits greater indemnification or advancement of
Expenses than would be afforded currently under the Company’s certificate of incorporation and bylaws and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by
such change, subject to the restrictions expressly set forth herein or therein. Except as expressly set forth herein, no right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy
shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. Except as expressly set forth herein, the assertion or employment of any right or remedy hereunder, or
otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy. 
 15. [Primary Responsibility. The
Company acknowledges that Indemnitee has certain rights to indemnification and advancement of expenses provided by [insert name of fund] [and certain affiliates thereof] (collectively, the “Secondary Indemnitor[s]”).
The Company agrees that, as between the Company and the Secondary Indemnitor[s], the Company is primarily responsible for amounts required to be indemnified or advanced under the Company’s certificate of incorporation or bylaws or this
Agreement and any obligation of the Secondary Indemnitor[s] to provide indemnification or advancement for the same amounts is secondary to those Company obligations. To the extent not in contravention of any insurance policy or policies providing
liability or other insurance for the Company or any director, trustee, general partner, managing member, officer, employee, agent or fiduciary of the Company or any other Enterprise, the Company waives any right of contribution or subrogation
against the Secondary Indemnitor[s] with respect to the liabilities for which the Company is primarily responsible under this Section 15. In the event of any payment by the Secondary Indemnitor[s] of amounts otherwise required to be indemnified
or advanced by the Company under the Company’s certificate of incorporation or bylaws or this Agreement, the Secondary Indemnitor[s] shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee for
indemnification or advancement of expenses under the Company’s certificate of incorporation or bylaws or this Agreement or, to the extent such subrogation is unavailable and contribution is found to be the applicable remedy, shall have a right
of contribution with respect to the amounts paid; provided, however, that the foregoing sentence will be deemed void if and to the extent that it would violate any applicable insurance policy. The Secondary Indemnitor[s] [are][is an] express
third-party [beneficiaries][beneficiary] of the terms of this Section 15.] 

  
 -11- 

 16. No Duplication of Payments. The Company shall not be liable under this Agreement
to make any payment of amounts otherwise indemnifiable hereunder (or for which advancement is provided hereunder) if and to the extent that Indemnitee has otherwise actually received payment for such amounts under any insurance policy, contract,
agreement or otherwise. 
 17. Insurance. To the extent that the Company maintains an insurance policy or policies providing
liability insurance for directors, trustees, general partners, managing members, officers, employees, agents or fiduciaries of the Company or any other Enterprise, Indemnitee shall be covered by such policy or policies to the same extent as the most
favorably-insured persons under such policy or policies in a comparable position. 
 18. Subrogation. In the event of any payment
under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of
such documents as are necessary to enable the Company to bring suit to enforce such rights. 
 19. Services to the Company.
Indemnitee agrees to serve as a director or officer of the Company or, at the request of the Company, as a director, trustee, general partner, managing member, officer, employee, agent or fiduciary of another Enterprise, for so long as Indemnitee is
duly elected or appointed or until Indemnitee tenders his or her resignation or is removed from such position. Indemnitee may at any time and for any reason resign from such position (subject to any other contractual obligation or any obligation
imposed by operation of law), in which event the Company shall have no obligation under this Agreement to continue Indemnitee in such position. This Agreement shall not be deemed an employment contract between the Company (or any of its subsidiaries
or any Enterprise) and Indemnitee. Indemnitee specifically acknowledges that any employment with the Company (or any of its subsidiaries or any Enterprise) is at will, and Indemnitee may be discharged at any time for any reason, with or without
cause, with or without notice, except as may be otherwise expressly provided in any executed, written employment contract between Indemnitee and the Company (or any of its subsidiaries or any Enterprise), any existing formal severance policies
adopted by the Company’s board of directors or, with respect to service as a director or officer of the Company, the Company’s certificate of incorporation or bylaws or the DGCL. No such document shall be subject to any oral modification
thereof. 
 20. Duration. This Agreement shall continue in effect until the later of (a) ten years after the date that
Indemnitee shall have ceased to serve as a director or an officer of the Company or as a director, trustee, general partner, managing member, officer, employee, agent or fiduciary of any other Enterprise, as applicable, (b) for as long as
Indemnitee may be subject to any Proceeding, even after Indemnitee has ceased to serve as a director or officer of the Company or as a director, trustee, general partner, managing member, officer, employee, agent or fiduciary of any other
Enterprise, as applicable. 
 21. Successors. This Agreement shall be binding upon the Company and its successors and assigns,
including any direct or indirect successor, by purchase, merger, consolidation or otherwise, to all or substantially all of the business or assets of the Company, and shall inure to the benefit of Indemnitee and Indemnitee’s heirs, executors
and administrators. The Company shall require and cause any successor (whether direct or indirect by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company, by written agreement, expressly
to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no such succession had taken place. 

  
 -12- 

 22. Severability. Nothing in this Agreement is intended to require or shall be
construed as requiring the Company to do or fail to do any act in violation of applicable law. The Company’s inability, pursuant to court order or other applicable law, to perform its obligations under this Agreement shall not constitute a
breach of this Agreement. If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (i) the validity, legality and enforceability of the remaining provisions of this
Agreement (including without limitation, each portion of any section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected
or impaired thereby and shall remain enforceable to the fullest extent permitted by law; (ii) such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the
intent of the parties hereto; and (iii) to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any section of this Agreement containing any such provision held to be invalid, illegal or
unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby. 

23. Enforcement. The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed
on it hereby in order to induce Indemnitee to serve as a director or officer of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as a director or officer of the Company. 

24. Entire Agreement. This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter
hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof; provided, however, that this Agreement is a supplement to and in furtherance of
the Company’s certificate of incorporation and bylaws and applicable law. 
 25. Modification and Waiver. No supplement,
modification or amendment to this Agreement shall be binding unless executed in writing by the parties hereto. No amendment, alteration or repeal of this Agreement shall adversely affect any right of Indemnitee under this Agreement in respect of any
action taken or omitted by such Indemnitee in his or her Corporate Status prior to such amendment, alteration or repeal. No waiver of any of the provisions of this Agreement shall constitute or be deemed a waiver of any other provision of this
Agreement nor shall any waiver constitute a continuing waiver. 
 26. Notices. All notices and other communications required or
permitted hereunder shall be in writing and shall be mailed by registered or certified mail, postage prepaid, sent by electronic mail or otherwise delivered by hand, messenger or courier service addressed: 

(a) if to Indemnitee, to Indemnitee’s address, or electronic mail address as shown on the signature page of this Agreement or in the
Company’s records, as may be updated in accordance with the provisions hereof; or 

  
 -13- 

 (b) if to the Company, to the attention of the Chief Executive Officer or Chief Financial
Officer of the Company at 2361 Hanover Street, Palo Alto, California 94304, or at such other current address as the Company shall have furnished to Indemnitee, with copies (which shall not constitute notice) to Jeffrey Saper and Michael Nordtvedt,
Wilson Sonsini Goodrich & Rosati, P.C., 650 Page Mill Road, Palo Alto, California 94304. 
 Each such notice or other communication
shall for all purposes of this Agreement be treated as effective or having been given (i) if delivered by hand, messenger or courier service, when delivered (or if sent via a nationally-recognized overnight courier service, freight
prepaid, specifying next-business-day delivery, one business day after deposit with the courier), or (ii) if sent via mail, at the earlier of its receipt or five days after the same has been
deposited in a regularly-maintained receptacle for the deposit of the United States mail, addressed and mailed as aforesaid, or (iii) if sent via electronic mail, upon confirmation of delivery when directed to the relevant electronic
mail address, if sent during normal business hours of the recipient, or if not sent during normal business hours of the recipient, then on the recipient’s next business day. 

27. Applicable Law and Consent to Jurisdiction. This Agreement and the legal relations among the parties shall be governed by, and
construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. Except with respect to any arbitration commenced by Indemnitee pursuant to Section 12(a) of this Agreement, the Company
and Indemnitee hereby irrevocably and unconditionally (i) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Delaware Court of Chancery, and not in any other state or federal
court in the United States of America or any court in any other country, (ii) consent to submit to the exclusive jurisdiction of the Delaware Court of Chancery for purposes of any action or proceeding arising out of or in connection with this
Agreement, (iii) appoint, to the extent such party is not otherwise subject to service of process in the State of Delaware, the Corporation Service Company, Wilmington, Delaware as its agent in the State of Delaware as such party’s agent
for acceptance of legal process in connection with any such action or proceeding against such party with the same legal force and validity as if served upon such party personally within the State of Delaware, (iv) waive any objection to the
laying of venue of any such action or proceeding in the Delaware Court of Chancery, and (v) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court of Chancery has been brought in an
improper or inconvenient forum. 
 28. Counterparts. This Agreement may be executed in one or more counterparts, each of which shall
for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. This Agreement may also be executed and delivered by facsimile signature and in counterparts, each of which shall for all purposes be
deemed to be an original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement.

 29. Captions. The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to
constitute part of this Agreement or to affect the construction thereof. 
 (signature page follows) 

  
 -14- 

 The parties are signing this Indemnification Agreement as of the date stated in the
introductory sentence. 
  

	
	KODIAK SCIENCES INC.
	
	   

	 (Signature)

	
	   

	 (Print name)

	
	   

	 (Title)

  

	
	[INSERT INDEMNITEE NAME]
	
	   

	 (Signature)

	
	   

	 (Print name)

	
	   

	 (Street address)

	
	   

	 (City, State and ZIP)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}]]